{"text": "[ 11 ] [ Level of evidence : 3iiiA ] .A retrospective analysis of 181 patients enrolled in prospective phase II and III GERCOR studies revealed that 29 % had metastatic disease after 3 months of gemcitabine - based chemotherapy .", "label": "", "metadata": {}, "score": "40.1901"}
{"text": "In the study , 861 patients with pancreatic cancer that had spread to the liver were randomly assigned to receive nab - paclitaxel ( paclitaxel protein - bound particles ) plus gemcitabine or gemcitabine alone .", "label": "", "metadata": {}, "score": "41.765213"}
{"text": "Redman BG , Smith DC , Flaherty L , et al .: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma .", "label": "", "metadata": {}, "score": "43.13385"}
{"text": "Currently , 57 patients have been enrolled and randomized for this trial , and recruitment is ongoing .PR : .Partial response .RECIST : .", "label": "", "metadata": {}, "score": "44.07514"}
{"text": "Page 6 .Although platinum - based agents remains dominant , taxanes have emerged as the second - most important class of agents in EOC , and carboplatin with paclitaxel was selected as the point of refer- ence for this trial .", "label": "", "metadata": {}, "score": "44.249725"}
{"text": "In the nab - paclitaxel / gemcitabine group , the median time from grade 3 neuropathy to grade 1 or resolution was 29 days .Of patients with grade 3 peripheral neuropathy , 44 % were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event .", "label": "", "metadata": {}, "score": "44.34722"}
{"text": "Piccart MJ , Bertelsen K , James K , et al : Randomized intergroup trial of cisplatin - paclitaxel versus cisplatin - cyclophosphamide in women with advanced epithelial ovarian cancer : Three - year re- sults .", "label": "", "metadata": {}, "score": "44.5282"}
{"text": "In 2013 , preliminary results of a pilot study of sequential neoadjuvant chemotherapy with nab - paclitaxel plus gemcitabine followed by FOLFIRINOX in locally advanced pancreatic cancer were presented [ 21 ] .", "label": "", "metadata": {}, "score": "44.990837"}
{"text": "This trial included only patients with metastatic disease ; therefore data about the efficacy of nab - paclitaxel in patients with locally advanced disease are lacking .", "label": "", "metadata": {}, "score": "45.27819"}
{"text": "GOG 204 -Randomized Phase III Study of Paclitaxel Plus Cisplatin vs. Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin vs. Topotecan Plus Cisplatin in Stage IVB , Recurrent , or Persistent Carcinoma of the Cervix .", "label": "", "metadata": {}, "score": "45.445427"}
{"text": "A 63-year - old Caucasian female with advanced poorly differentiated pNET ( liver , lymph nodes , peritoneal ) , was treated with a combination of etoposide and cisplatin as first - line chemotherapy .", "label": "", "metadata": {}, "score": "45.578384"}
{"text": "These decisions were based on practical aspects of con- ducting an international cooperative group trial as well as on the cumulative risksofcarboplatin - inducedthrombocytopenia .Gemcitabine was evaluated in two experimental arms , as a triplet com- binationineightcycles , andasasequentialdoubletinfourcycles , administered on days 1 and 8 .", "label": "", "metadata": {}, "score": "46.087112"}
{"text": "Vasey PA , Jayson GC , Gordon A , et al : Phase III randomized trial of docetaxel - carboplatin versus paclitaxel - carboplatin as first - line chemotherapy for ovarian carcinoma .", "label": "", "metadata": {}, "score": "46.488907"}
{"text": "RESULTS The study was activated in January 2001 , and the first patient was enrolled in February 2001 ( Table 1 ) .The planned interim analysis of PFSoccurredwhentherewere272events(ie , progressionordeath)on the reference arm and 1,345 cumulative events among 3,836 patients ( data freeze on May 2004 ) .", "label": "", "metadata": {}, "score": "47.05771"}
{"text": "A phase II trial evaluated the combination of cisplatin and gemcitabine followed by gemcitabine - based chemoradiotherapy in 90 patients with resectable PDAC .Sixty - two ( 78 % ) of 79 patients who completed chemoradiation were taken to surgery and 52 ( 66 % ) of 79 underwent PD .", "label": "", "metadata": {}, "score": "47.563576"}
{"text": "Received June 5 th , 2013 - Accepted October 12 th , 2013 .Key words Carcinoid Tumor ; Drug Therapy ; gemcitabine ; Neuroendocrine Tumors ; Pancreatic Neoplasms .", "label": "", "metadata": {}, "score": "47.62948"}
{"text": "Hoskins PJ , Vergote I , Stuart G , et al : A phase III trial of cisplatin plus topotecan followed by pacli- taxel plus carboplatin versus standard carboplatin plus paclitaxel as first - line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer ( EOC ) ( OV .", "label": "", "metadata": {}, "score": "47.79861"}
{"text": "An event - triggered interim analysis occurred after 272 events on the reference arm , and the study closed with 4,312 women enrolled .Arms were well balanced for demographic and prognostic factors , and 79 % of patients completed eight cycles of therapy .", "label": "", "metadata": {}, "score": "47.971535"}
{"text": "An event - triggered interim analysis occurred after 272 events on the reference arm , and the study closed with 4,312 women enrolled .Arms were well balanced for demographic and prognostic factors , and 79 % of patients completed eight cycles of therapy .", "label": "", "metadata": {}, "score": "47.971535"}
{"text": "Loehrer PJ Sr , Einhorn LH , Elson PJ , et al .: A randomized comparison of cisplatin alone or in combination with methotrexate , vinblastine , and doxorubicin in patients with metastatic urothelial carcinoma : a cooperative group study .", "label": "", "metadata": {}, "score": "48.193127"}
{"text": "Conclusions .Trial registration .Keywords .Liposomal paclitaxel Cisplatin Gemcitabine Regional lymph node metastasis Trials .Background .Regional lymphatic metastasis was generally involved in patients with NSCLC .", "label": "", "metadata": {}, "score": "48.361607"}
{"text": "Although platinum - based agents ( ie , cisplatin or carboplatin ) and taxanes remain the core of primary treatment , clinical trials have incorpo- ratedothercytotoxicagents , includingtopotecan , gemcitabine , and methoxypolyethylene glycosy- lated liposomal doxorubicin ( PLD ) .", "label": "", "metadata": {}, "score": "48.453327"}
{"text": "Survival analyses of groups defined by size of residual disease also failed to show experimental benefit in any subgroup .Compared with standard paclitaxel and carboplatin , addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction .", "label": "", "metadata": {}, "score": "48.588806"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00003930 .Kaufman DS , Winter KA , Shipley WU , et al .: Muscle - invading bladder cancer , RTOG Protocol 99 - 06 : initial report of a phase I / II trial of selective bladder - conservation employing TURBT , accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy .", "label": "", "metadata": {}, "score": "48.628265"}
{"text": "Gatzemeier U , von Pawel J , Gottfried M et al ( 2000 )Phase III comparative study of high - dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "48.762035"}
{"text": "Biometika 68:316 - 319 , 1981 14 .McGuire WP , Hoskins WJ , Brady MF , et al : Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer .", "label": "", "metadata": {}, "score": "48.76243"}
{"text": "This is a prospective , open - label , controlled randomized clinical trial ( RCT ) to assess the therapeutic effects and safety of liposomal paclitaxel .", "label": "", "metadata": {}, "score": "48.892986"}
{"text": "19 , pp .1817 - 1825 , 2011 .View at Publisher \u00b7 View at Google Scholar . D. D. von Hoff , T. Ervin , F. P. Arena , et al . , \" Increased survival in pancreatic cancer with nab - paclitaxel plus gemcitabine , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "49.096333"}
{"text": "Look KY , Bookman MA , Schol J , et al : Phase I feasibility trial of carboplatin , paclitaxel , and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer : A Gynecologic Oncology Group study .", "label": "", "metadata": {}, "score": "49.12498"}
{"text": "8013 ) .Johnson DH , Fehrenbacher L , Novotny WF et al ( 2004 )Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "49.25505"}
{"text": "Sandler AB , Nemunaitis J , Denham C et al ( 2000 ) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "49.50264"}
{"text": "A study by Moertel et al . reported that etoposide plus cisplatin produced a remission in 55 - 80 % of patients , with response duration of 8 - 11 months [ 5].", "label": "", "metadata": {}, "score": "49.503803"}
{"text": "Cancer 92(10):2639 - 2647 PubMed CrossRef .Langer C , Li S , Schiller J , Tester W , Rapoport BL , Johnson DH ( 2007 ) Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non - small - cell lung cancer patients : ECOG 1599 .", "label": "", "metadata": {}, "score": "49.520966"}
{"text": "All patients received the planned 4 cycles of neoadjuvant chemotherapy without dose reductions and there were no treatment - related deaths and none of the patients stopped treatment due to toxicity .", "label": "", "metadata": {}, "score": "49.548332"}
{"text": "Survival analyses of groups defined by size of residual disease also failed to show experimental benefit in any subgroup .Conclusion Compared with standard paclitaxel and carboplatin , addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction .", "label": "", "metadata": {}, "score": "49.668137"}
{"text": "The trial will be comprised of three phases as follows .Phase 1 ( recruitment and assignment of patients ) .Consenting eligible participants will be recruited in accordance with the inclusion / exclusion criteria and assigned randomly to one of the two treatment groups .", "label": "", "metadata": {}, "score": "49.67394"}
{"text": "( 1995 ) Chemotherapy in non - small cell lung cancer : a meta - analysis using updated data on individual patients from 52 randomised clinical trials .", "label": "", "metadata": {}, "score": "49.756653"}
{"text": "Butts CA , Bodkin D , Middleman EL et al ( 2007 ) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [ corrected ] , with or without cetuximab , as first - line therapy for patients with advanced or metastatic non small - cell lung cancer .", "label": "", "metadata": {}, "score": "49.855553"}
{"text": "Page 3 . for interval - debulking surgery .Annual accrual was estimated to be 1,000 patients , with50%accruedfromcollaboratinggroups .Theestimatedmedian timetoprogressionordeathforwomenwithadvanced - stageEOCwhowere receiving carboplatin and paclitaxel was 15 months , and estimated median survival was 36 months .", "label": "", "metadata": {}, "score": "50.122143"}
{"text": "Sandler A , Gray R , Perry MC et al ( 2006 )Paclitaxel - carboplatin alone or with bevacizumab for non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "50.168716"}
{"text": "View Article .Zeng X , Li Z , Hou M : [ A randomized clinical trial on the clinical efficacy and toxicities of single - agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first - line chemotherapy for advanced non - small cell lung cancer in elderly patients].", "label": "", "metadata": {}, "score": "50.619278"}
{"text": "Platinum - based combination chemotherapy regimens are the standard of care .[ 4 ] The ( outpatient ) regimen of paclitaxel and carboplatin achieved response rates in the range of 50 % in single - institution phase II trials .", "label": "", "metadata": {}, "score": "50.846825"}
{"text": "In particular , the dramatically higher drug concentration in the lymph nodes compared with the current paclitaxel formulations indicates that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug .", "label": "", "metadata": {}, "score": "50.98558"}
{"text": "Preliminary development for GOG0182-ICON5 , including phase I trials , was coordinated largely through GOG .Final protocol developmentwasaccomplishedwithcollaborationfromGCIGmem- bers .Accrual was facilitated by joint enrollment of patients who had optimal and suboptimal residual disease .", "label": "", "metadata": {}, "score": "51.056694"}
{"text": "Kelly K , Crowley J , Bunn PA Jr et al ( 2001 ) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small - cell lung cancer : a Southwest Oncology Group trial .", "label": "", "metadata": {}, "score": "51.171448"}
{"text": "After the patient 's eligibility for enrollment has been assessed , a unique randomization number will be sent to our department through this central randomization system , and the patient will be assigned to the appropriate treatment group , thus each group will be allocated 63 participants .", "label": "", "metadata": {}, "score": "51.1797"}
{"text": "Approximately 45 individual trials are active at any on time within the GOG for patients with a variety of gynecologic malignancies , including cancers that arise from the ovaries , uterus , cervix , vagina and vulva .", "label": "", "metadata": {}, "score": "51.206512"}
{"text": "Sternberg CN , Calabr\u00f2 F , Pizzocaro G , et al .: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin - based therapy .", "label": "", "metadata": {}, "score": "51.506996"}
{"text": "We did not find any clinical randomized controlled trial ( RCT ) to date that had examined the role of liposomal paclitaxel in patients with NSCLC with regional lymphatic metastasis .", "label": "", "metadata": {}, "score": "51.515556"}
{"text": "Bonomi P , Kim K , Fairclough D et al ( 2000 ) Comparison of survival and quality of life in advanced non - small - cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin : results of an Eastern Cooperative Oncology Group trial .", "label": "", "metadata": {}, "score": "51.903862"}
{"text": "A high response rate was observed ( 47 % ) while stable disease was reported in 42 % of patients .Thirteen patients of ninety - one included in the analysis ( 14 % ) were radically resected yielding one pathologic complete remission [ 33 ] .", "label": "", "metadata": {}, "score": "52.049507"}
{"text": "Pharmacokinetic studies in animal models [ 10 - 12 ] have shown that , compared with the current paclitaxel formulation , liposomal paclitaxel has a significantly prolonged elimination half - life and mean retention time , and an apparent larger volume of distribution .", "label": "", "metadata": {}, "score": "52.077824"}
{"text": "Case # 2 .A 56-year - old Caucasian male with a diagnosis of metastatic poorly differentiated pNET ( para - aortic lymph nodes ) was treated with a combination of etoposide and cisplatin as first - line chemotherapy .", "label": "", "metadata": {}, "score": "52.128315"}
{"text": "17 ] [ Level of evidence : 1iiA ] .The corresponding median survival rate for patients receiving erlotinib was 6.2 months , versus 5.9 months for patients receiving placebo .", "label": "", "metadata": {}, "score": "52.48575"}
{"text": "Ozols RF , Bundy BN , Greer BE , et al : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : A Gynecologic Oncology Group study .", "label": "", "metadata": {}, "score": "52.553146"}
{"text": "Study duration .Ongoing recruitment will continue for a maximum of 12 months ( between June 2012 and June 2013 ) or until 126 individuals have been randomly assigned .", "label": "", "metadata": {}, "score": "52.563244"}
{"text": "Yang MH , Yen CC , Chang YH , et al .: Single agent paclitaxel as a first - line therapy in advanced urothelial carcinoma : its efficacy and safety in patients even with pretreatment renal insufficiency .", "label": "", "metadata": {}, "score": "52.636177"}
{"text": "The patient remained in Eastern Cooperative Oncology Group ( ECOG ) performance status of 1 .Phase I studies were offered which he declined and therefore , other treatment options including irinotecan , gemcitabine and paclitaxel were offered .", "label": "", "metadata": {}, "score": "52.63746"}
{"text": "619 - 627 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. J. Kim , E. Ben - Josef , J. M. Herman et al . , \" A multi - institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer , \" Cancer , vol .", "label": "", "metadata": {}, "score": "52.66525"}
{"text": "With a 2 \u00d7 2 factorial design reported at a median follow - up of 47 months , a median survival benefit was observed for only the patients who received postoperative 5-FU chemotherapy .", "label": "", "metadata": {}, "score": "52.67511"}
{"text": "6 , pp .776 - 784 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. H. Palmer , D. D. Stocken , H. Hewitt et al . , \" A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer : gemcitabine alone versus gemcitabine combined with cisplatin , \" Annals of Surgical Oncology , vol .", "label": "", "metadata": {}, "score": "52.724216"}
{"text": "View at Google Scholar .V. Kunzmann , I. Hartlapp , M. Scheurlen , et al . , \" Sequential neoadjuvant chemotherpy with nab - paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer ( LAPC ) : a PILOT study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "52.76207"}
{"text": "Subjects .The study aims to enroll 126 patients with NSCLC who meet both the inclusion and exclusion criteria below .Using a random - number table ( Center of Evidence - Based Medicine and Clinical Epidemiology , The Second Affiliated Hospital , Chongqing ) , patients will be randomly assigned in a 1:1 ratio to either the LP or the GP group ( Figure 1 ) .", "label": "", "metadata": {}, "score": "52.781403"}
{"text": "Demographic , stratification , and prognostic factors were well balanced among treatment arms ( Fig 1 ) .Of note , consistent with current surgical trends , 70 % of women who were registered had optimal cytoreduction , and less than 25 % of women had measur- able residual disease .", "label": "", "metadata": {}, "score": "52.86739"}
{"text": "Piccart MJ , Bertelsen K , Stuart G , et al : Long - term follow - up confirms a survival advan- tage of the paclitaxel - cisplatin regimen over the cyclophosphamide - cisplatin combination in advanced ovarian cancer .", "label": "", "metadata": {}, "score": "52.888374"}
{"text": "At 12 weeks postconsolidation therapy or 8 weeks post radical cystectomy , patients receive adjuvant chemotherapy comprising gemcitabine IV over 30 - 60 minutes followed by cisplatin IV over 1 hour every 3 weeks .", "label": "", "metadata": {}, "score": "53.150414"}
{"text": "[ 3 ] [ Level of evidence : 1iiA ] ; [ 4 ] [ Level of evidence : 2A ] .The investigators reported a significant but modest improvement in median - term and long - term survival over resection alone with postoperative bolus 5-FU and regional split - course radiation given at a dose of 40 Gy .", "label": "", "metadata": {}, "score": "53.219162"}
{"text": "Socinski MA , Schell MJ , Peterman A et al ( 2002 ) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second - line therapy in advanced - stage IIIB / IV non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "53.537613"}
{"text": "Notably , the phase III study by Conroy et al . included only patients with metastatic disease and then results can not be translated to LAPC patients .", "label": "", "metadata": {}, "score": "53.601273"}
{"text": "If the combination of etoposide and cisplatin as the first - line chemotherapy fails to treat these patients , no consensus exists to define second or further treatment recommendations .", "label": "", "metadata": {}, "score": "53.833515"}
{"text": "Brodowicz T , Krzakowski M , Zwitter M et al ( 2006 ) Cisplatin and gemcitabine first - line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non - small cell lung cancer : a phase III trial .", "label": "", "metadata": {}, "score": "53.880253"}
{"text": "It has been approved by the FDA for the treatment of metastatic colorectal cancers , but only in patients without mutations in the KRAS protein , because mutations in KRAS render the drug ineffective .", "label": "", "metadata": {}, "score": "54.05873"}
{"text": "A randomized phase II study .Cancer 77 ( 2 ) : 344 - 51 , 1996 .Bellmunt J , Ribas A , Eres N , et al .", "label": "", "metadata": {}, "score": "54.1847"}
{"text": ":A multi - institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer .Urol Oncol 22 ( 5 ) : 393 - 7 , 2004 Sep - Oct .", "label": "", "metadata": {}, "score": "54.237556"}
{"text": "15 , pp .2692 - 2700 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Louvet , R. Labianca , P. Hammel et al . , \" Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer : results of a GERCOR and GISCAD phase III trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.281223"}
{"text": "NSCLC Meta - Analyses Collaborative Group ( 2008 )Chemotherapy in addition to supportive care improves survival in advanced non - small - cell lung cancer : a systematic review and meta - analysis of individual patient data from 16 randomized controlled trials .", "label": "", "metadata": {}, "score": "54.354485"}
{"text": "New results reported this year , however , indicate that mutations in a related protein , NRAS , also interfere with the efficacy of panitumumab .", "label": "", "metadata": {}, "score": "54.38176"}
{"text": "Regine WF , Winter KA , Abrams R , et al .: Fluorouracil - based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma : 5-year analysis of the U.S. Intergroup / RTOG 9704 phase III trial .", "label": "", "metadata": {}, "score": "54.383793"}
{"text": "In the absence of any published randomized controlled trials showing improved outcomes with a noncisplatin regimen , it is impossible to know whether any of those regimens benefit patients .", "label": "", "metadata": {}, "score": "54.414185"}
{"text": "The patients were assigned to one of four groups ( observation , bolus 5-FU chemotherapy , bolus 5-FU chemoradiation therapy , or chemoradiation therapy followed by additional chemotherapy ) .", "label": "", "metadata": {}, "score": "54.62179"}
{"text": "In view of the pharmacokinetic characteristics of liposomal paclitaxel in lymph nodes , we speculate that this new formulation may represent a novel chemotherapy drug , and could play a unique role in the treatment of NSCLC with regional lymphatic metastasis .", "label": "", "metadata": {}, "score": "54.623592"}
{"text": "10 , pp .2537 - 2544 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Mizuma , F. Motoi , and K. Ishida , \" Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : a prospective , multi - institutional , phase II trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.666023"}
{"text": "Patients will receive four to six cycles of the assigned chemotherapy , and primary outcome will be assessed every two cycles .Patients will be recommended for surgery if the tumor becomes resectable .", "label": "", "metadata": {}, "score": "54.789726"}
{"text": "21 , pp .3487 - 3495 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. W. T. Pisters , R. A. Wolff , N. A. Janjan et al . , \" Preoperative paclitaxel and concurrent rapid - fractionation radiation for resectable pancreatic adenocarcinoma : Toxicities , histologic response rates , and event - free outcome , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.992485"}
{"text": "Over the past decades , a number of systemic treatment options for incurable , advanced non - small cell lung cancer have been developed .While untreated patients with this disease typically have a median overall survival of 4.5 months , this figure has exceeded the 12-month mark in the latest randomized phase III trials .", "label": "", "metadata": {}, "score": "55.02364"}
{"text": "Official Title : .A Phase I / II Trial in Patients With Muscle - Invading Bladder Cancer of Transurethral Surgery Plus Taxol , Cisplatin and Bid Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy .", "label": "", "metadata": {}, "score": "55.026985"}
{"text": "One common practice has been to substitute carboplatin for cisplatin to reduce nephrotoxicity and gastrointestinal toxicity .Two small , randomized trials comparing cisplatin - based regimens to carboplatin - based regimens have been published .", "label": "", "metadata": {}, "score": "55.03168"}
{"text": "[ 16 ] However , patients with a performance status of 2 and a creatinine clearance less than 60 mL / min had a response rate of only 26 % and 20 % , respectively and a severe acute toxicity rate of 26 % and 25 % , respectively .", "label": "", "metadata": {}, "score": "55.042473"}
{"text": "However , these studies were underpowered , and the one that showed a disease - specific survival difference included an anthracycline in the cisplatin arm but not in the carboplatin arm .", "label": "", "metadata": {}, "score": "55.060562"}
{"text": "Kelsen D , Hudis C , Niedzwiecki D , et al .: A phase III comparison trial of streptozotocin , mitomycin , and 5-fluorouracil with cisplatin , cytosine arabinoside , and caffeine in patients with advanced pancreatic carcinoma .", "label": "", "metadata": {}, "score": "55.093452"}
{"text": "This schedule was chosen because of relatively young age and excellent performance status .After two cycles of gemcitabine ( 8 weeks ) , a CT scan of his abdomen showed stable disease .", "label": "", "metadata": {}, "score": "55.216236"}
{"text": "Ineligible patients ( N ?212 ) included 83 patients with insufficient pathology material to document eligibility , 43 with inappropriate histology , 22 with inadequate staging surgery , 22 with ineligible primary tumor site , 21 with ineligible stage , 14 with second primary site , and seven ineligible for other reasons .", "label": "", "metadata": {}, "score": "55.254448"}
{"text": "In a study on 35 patients , paclitaxel ( weekly 3 h infusion of 60 mg / m 2 for 3 consecutive weeks ) concomitant to radiotherapy ( 30 Gy ) was administered before surgery .", "label": "", "metadata": {}, "score": "55.332314"}
{"text": "Relapse rates were also lower in the S-1 arm .The 2-year relapse - free survival rates were 49 % and 29 % for S-1 and gemcitabine , respectively .", "label": "", "metadata": {}, "score": "55.36161"}
{"text": ": Gemcitabine and cisplatin versus methotrexate , vinblastine , doxorubicin , and cisplatin in advanced or metastatic bladder cancer : results of a large , randomized , multinational , multicenter , phase III study .", "label": "", "metadata": {}, "score": "55.513268"}
{"text": "J Natl Cancer Inst 91(1):66 - 72 .Ranson M , Davidson N , Nicolson M et al ( 2000 ) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "55.636723"}
{"text": "Belani CP , Barstis J , Perry MC et al ( 2003 )Multicenter , randomized trial for stage IIIB or IV non - small - cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation .", "label": "", "metadata": {}, "score": "55.64573"}
{"text": "CASE SERIES .Case # 1 .A 67-year - old Hispanic male with locally advanced poorly differentiated pNET ( encasement of superior mesenteric vessels and lymph nodes ) , was treated with a combination of etoposide and carboplatin as first - line chemotherapy .", "label": "", "metadata": {}, "score": "55.89691"}
{"text": "Small EJ , Lew D , Redman BG , et al .: Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional - cell carcinoma : the importance of survival as a clinical trial end point .", "label": "", "metadata": {}, "score": "55.96249"}
{"text": "Fossella F , Pereira JR , von Pawel J et al ( 2003 ) Randomized , multinational , phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non - small - cell lung cancer : the TAX 326 study group .", "label": "", "metadata": {}, "score": "55.969704"}
{"text": "Smith IE , O'Brien ME , Talbot DC et al ( 2001 ) Duration of chemotherapy in advanced non - small - cell lung cancer : a randomized trial of three versus six courses of mitomycin , vinblastine , and cisplatin .", "label": "", "metadata": {}, "score": "56.00284"}
{"text": "Lynch TJ , Patel T , Dreisbach L , et al ( 2007 )A randomized multicenter phase III study of cetuximab ( Erbitux \u00ae ) in combination with Taxane / Carboplatin versus Taxane / Carboplatin alone as first - line treatment for patients with advanced / metastatic non - small cell lung cancer ( NSCLC ) .", "label": "", "metadata": {}, "score": "56.061897"}
{"text": "A total of 16 patients ( 46 % ) proceeded to surgery , with 88 % with an R0 resection and median overall survival of 23 months .", "label": "", "metadata": {}, "score": "56.096123"}
{"text": "CP , carboplatin and paclitaxel ; CPG , carboplatin , paclitaxel , and gemcitabine ; CPD , carboplatin , pac- litaxel , and doxorubicin ; CT - CP , carboplatin plus topotecan , then carboplatin plus paclitaxel ; CG - CP , carboplatin plus gemcitabine , then carboplatin plus paclitaxel .", "label": "", "metadata": {}, "score": "56.10759"}
{"text": "On the whole , the results were less promising compared to what was observed with 5-FU based therapy [ 14 ] .Recently , results of a phase II trial evaluating gemcitabine and S-1 in this setting in an Asian population have been presented .", "label": "", "metadata": {}, "score": "56.171738"}
{"text": "A recent systematic review has evaluated 111 trials including 4394 pancreatic cancer patients [ 35 ] .Neoadjuvant therapy included chemotherapy in 96 % and radiation therapy in 94 % of studies .", "label": "", "metadata": {}, "score": "56.174408"}
{"text": "Trials main menu .Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first - line chemotherapy for patients with advanced NSCLC with regional lymph - node metastasis : study protocol for a randomized controlled trial ( PLC - GC trial ) .", "label": "", "metadata": {}, "score": "56.192944"}
{"text": "19 ] .Distant relapse remained the predominant site of first failure ( 78 % ) .A secondary analysis of RTOG-9704 explored the correlation of adherence to protocol - specified radiation with patient outcomes .", "label": "", "metadata": {}, "score": "56.277916"}
{"text": "Not one of these phase III trials has demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first - line treatment of metastatic pancreatic cancer .", "label": "", "metadata": {}, "score": "56.333042"}
{"text": "In fact , it has been shown by adjuvant trials that up to 25 % of patients submitted to pancreatic resection do not receive the planned treatment due to postoperative complications , deterioration of performance status , comorbidities , or early recurrence [ 8 ] .", "label": "", "metadata": {}, "score": "56.550686"}
{"text": "Cormier Y , Eisenhauer E , Muldal A , Gregg R , Ayoub J , Goss G , Stewart D , Tarasoff P and Wong D : Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer ( SCLC ) .", "label": "", "metadata": {}, "score": "56.602386"}
{"text": "Manegold C , Pawel Jv , Zatloukal P , et al ( 2007 )Randomised , double - blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy - na\u00efve patients with advanced or recurrent non - squamous non - small cell lung cancer ( NSCLC ) : BO17704 .", "label": "", "metadata": {}, "score": "56.60404"}
{"text": "The ITT population , which will include all randomized patients , will be used for efficacy analysis .In addition , a per - protocol analysis will be performed on the efficacy endpoint .", "label": "", "metadata": {}, "score": "56.74177"}
{"text": "2088 - 2096 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Heinrich , B. C. Pestalozzi , M. Sch\u00e4fer et al . , \" Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "56.744385"}
{"text": "A mul- tiarm , multistage design to evaluate four different experimental arms against a single reference arm was proposed by the Gynecologic Oncology Group JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME27 ? NUMBER9 ?", "label": "", "metadata": {}, "score": "56.751163"}
{"text": "Subsequently , the same group evaluated neoadjuvant chemoradiotherapy with gemcitabine concomitant to radiation therapy ( 30 Gy ) on 86 patients with localized pancreatic cancer .", "label": "", "metadata": {}, "score": "56.76571"}
{"text": "Ongoing studies are evaluating new chemotherapy combinations .Chemotherapy for patients not eligible for cisplatin .The only regimens that have shown a survival benefit in randomized controlled trials have been the cisplatin - based multiagent regimens MVAC , high - dose MVAC , and CMV ; gemcitabine plus cisplatin is generally accepted as equivalent to MVAC based on the data discussed above .", "label": "", "metadata": {}, "score": "56.981018"}
{"text": "Gynecol Oncol 99:71 - 79 , 2005 5 .Rustin GJ , Timmers P , Nelstrop A , et al : Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclo- phosphamide .", "label": "", "metadata": {}, "score": "56.984486"}
{"text": "Scagliotti GV , Parikh P , von Pawel J et al ( 2008 )Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy - naive patients with advanced - stage non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "56.99362"}
{"text": "Ansell SM , Pitot HC , Burch PA , Kvols LK , Mahoney MR and Rubin J : A Phase II study of high - dose paclitaxel in patients with advanced neuroendocrine tumors .", "label": "", "metadata": {}, "score": "57.124966"}
{"text": "Lilenbaum RC , Langenberg P , Dickersin K ( 1998 )Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma : a meta - analysis of response , toxicity , and survival .", "label": "", "metadata": {}, "score": "57.204994"}
{"text": "GOG 129-N -Phase II Evaluation of Weekly Docetaxel in the Treatment of Recurrent or Persistent Endometrial Carcinoma .GOG 209 -Randomized Phase III Trial of Doxorubicin / Cisplatin / Paclitaxel and G - CSF vs. Carboplatin / Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer .", "label": "", "metadata": {}, "score": "57.27253"}
{"text": "DISCUSSION Maximal cytoreductive surgery and platinum - based chemotherapy remains the current global standard for management of advanced- stageEOCandPPC.Mature , phaseIIIdata14 - 16andameta - analysis17 established the superiority of cisplatin plus paclitaxel compared with cisplatin plus cyclophosphamide .", "label": "", "metadata": {}, "score": "57.329807"}
{"text": "All the three patients achieved clinical benefit with manageable toxicities .The survival was 5.5 , 8 , and 9 months respectively after the beginning of gemcitabine in these three patients .", "label": "", "metadata": {}, "score": "57.34665"}
{"text": "The chemotherapy will be given as four to six cycles in total , with every 21 days making up one cycle .One week after every two cycles , the efficacy should be evaluated in accordance with the RECIST criteria [ 19 ] .", "label": "", "metadata": {}, "score": "57.565304"}
{"text": "The CONKO-003 investigators randomly assigned patients in the second line of chemotherapy to either an OFF regimen or BSC .After a rest of 3 weeks , the next cycle was started on day 43 .", "label": "", "metadata": {}, "score": "57.579475"}
{"text": "None of the experimental regimens reduced the PFS event rate at least 7 % relative to the reference arm .Therefore , in Table 2 . of patients Randomly assigned Ineligible after review ?", "label": "", "metadata": {}, "score": "57.5908"}
{"text": "The results of this study may provide a new chemotherapy regimen for clinicians and promote new trials to focus on patients with NSCLC with regional lymphatic metastasis .", "label": "", "metadata": {}, "score": "57.648148"}
{"text": "Bukowski RM , Balcerzak SP , O'Bryan RM , et al .: Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer .", "label": "", "metadata": {}, "score": "57.667633"}
{"text": "Armstrong DK , Bookman MA , McGuire W , et al : A phase I study of paclitaxel , topotecan , cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies : A Gyneco- logic Oncology Group study .", "label": "", "metadata": {}, "score": "57.69098"}
{"text": "[26 ] on seventeen patients with BRPC .The patients were treated with three cycles of induction chemotherapy with gemcitabine , docetaxel , and capecitabine followed by 5-FU based chemoradiotherapy with IMRT .", "label": "", "metadata": {}, "score": "57.75334"}
{"text": "Patients will receive four to six cycles of chemotherapy with either LP or GP .Adverse events ( AEs ) will be rigorously monitored and recorded on a case report form ( CRF ) .", "label": "", "metadata": {}, "score": "57.847595"}
{"text": "Oettle H , Neuhaus P , Hochhaus A , et al .: Adjuvant chemotherapy with gemcitabine and long - term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial .", "label": "", "metadata": {}, "score": "57.855545"}
{"text": "21 ] [ Level of evidence : 1iiA ] .[ 8 ] [ Level of evidence : 1iiA ] .Additional trials are still warranted to determine more effective adjuvant therapy for this disease .", "label": "", "metadata": {}, "score": "57.866108"}
{"text": "Regine WF , Winter KA , Abrams RA , et al .: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil - based chemoradiation following resection of pancreatic adenocarcinoma : a randomized controlled trial .", "label": "", "metadata": {}, "score": "57.94246"}
{"text": "5 , pp .851 - 862 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Reni , S. Cereda , G. Balzano et al . , \" Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma , \" Cancer Chemotherapy and Pharmacology , vol .", "label": "", "metadata": {}, "score": "58.134495"}
{"text": "Fidias P , Dakhil S , Lyss A , et al ( 2007 ) Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non - small - cell lung cancer : updated report with survival .", "label": "", "metadata": {}, "score": "58.16371"}
{"text": "Median progression - free survival under FOLFIRI was 4 months .Overall survival was 18 vs .6.8 months in non eligible patients .However , this regimen is only limited to patients with near - normal liver function tests [ 21].", "label": "", "metadata": {}, "score": "58.1987"}
{"text": "Schiller JH , Harrington D , Belani CP et al ( 2002 ) Comparison of four chemotherapy regimens for advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "58.26927"}
{"text": "Among patients with initially nonresectable tumours , surgical exploration was performed in 47 % of cases .The overall resection rate after neoadjuvant therapy was 33 % , and 79 % of resections were R0 resections .", "label": "", "metadata": {}, "score": "58.2881"}
{"text": "Collaborating organizations within the United States also included the Southwest Oncology Group and five other groups managed through the Clinical Trials Support Unit of the National Cancer Institute(Table1 ) .", "label": "", "metadata": {}, "score": "58.319557"}
{"text": "Pfisterer J , Plante M , Vergote I , et al : Gemcit- abine plus carboplatin compared with carboplatin in patients with platinum - sensitive recurrent ovarian cancer : An intergroup trial of the AGO - OVAR , the NCIC CTG , and the EORTC GCG .", "label": "", "metadata": {}, "score": "58.4431"}
{"text": "Furthermore , a phase I study of preoperative gemcitabine plus CD40 agonist antibody CP-870,893 followed by addition of CP-870,893 to standard of care adjuvant chemoradiation is recruiting patients with newly diagnosed resectable PDAC ( NCT01456585 ) .", "label": "", "metadata": {}, "score": "58.60379"}
{"text": "Wozniak AJ , Crowley JJ , Balcerzak SP et al ( 1998 )Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non - small - cell lung cancer : a Southwest Oncology Group study .", "label": "", "metadata": {}, "score": "58.649063"}
{"text": "Prospective and controlled randomized trials using the most active chemotherapy regimens currently available are warranted to assess the benefit of neoadjuvant strategies compared to conventional adjuvant strategies in this setting .", "label": "", "metadata": {}, "score": "58.666245"}
{"text": "Following or during definitive therapy , the increase of CA 19 - 9 levels may identify patients with progressive tumor growth .[ 9 ] [ Level of evidence : 3iDiii ] The presence of a normal CA 19 - 9 , however , does not preclude recurrence .", "label": "", "metadata": {}, "score": "58.781494"}
{"text": "GOG 211 -Phase II Pilot Investigation of the Relationship of Short Term Depo - Provera Exposure to the Morphologic , Biological , and Molecular Changes in Primary endometrial Adenocarcinoma .", "label": "", "metadata": {}, "score": "58.794464"}
{"text": "The CONKO-003 investigators randomly assigned patients in the second line of chemotherapy to either the OFF regimen or BSC .After a rest of 3 weeks , the next cycle was started on day 43 .", "label": "", "metadata": {}, "score": "58.795624"}
{"text": "18 , pp .3776 - 3783 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Sahora , I. Kuehrer , A. Eisenhut et al . , \" NeoGemOx : gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced , nonmetastasized pancreatic cancer , \" Surgery , vol .", "label": "", "metadata": {}, "score": "58.802467"}
{"text": "Medical interventions .Based on the manufacturer 's instructions for use of liposomal paclitaxel , pretreatment with intravenous dexamethasone ( 5 to 10 mg ) , intravenous cimetidine ( 300 mg ) and intramuscular diphenhydramine ( 50 mg ) should be performed 30 minutes before chemotherapy .", "label": "", "metadata": {}, "score": "58.962135"}
{"text": "Ann Oncol .Masters GA , Declerck L , Blanke C , Sandler A , DeVore R , Miller K and Johnson D : Phase II trial of gemcitabine in refractory or relapsed small - cell lung cancer : Eastern Cooperative Oncology Group Trial 1597 .", "label": "", "metadata": {}, "score": "58.99652"}
{"text": "Sternberg CN , de Mulder P , Schornagel JH , et al .: Seven year update of an EORTC phase III trial of high - dose intensity M - VAC chemotherapy and G - CSF versus classic M - VAC in advanced urothelial tract tumours .", "label": "", "metadata": {}, "score": "59.066784"}
{"text": "Adapted from Yao JC et al . , 2008 [ 2 ] .Poorly differentiated pNETs are characterized by their aggressive tumor biology , absence of somatostatin receptors , and poor prognosis [ 4].", "label": "", "metadata": {}, "score": "59.07583"}
{"text": "GOG 175 -Randomized Phase III Trial of Carboplatin and Taxol Q 21 days for 3 courses Plus Low dose Paclitaxel vs. Carboplatin and Taxol Q 21 days for 3 courses Plus Observation in Patients with Early Stage Ovarian Cancer .", "label": "", "metadata": {}, "score": "59.08653"}
{"text": "The times will be increased if myelosuppression happens .During the treatment , tumor will be evaluated 1 week after every two cycles of chemotherapy , as described above .", "label": "", "metadata": {}, "score": "59.104446"}
{"text": "Patients are followed every 4 months for 1 year , every 6 months for 3 years , and then annually thereafter .PROJECTED ACCRUAL : A total of 84 patients will be accrued for this study within 3 years .", "label": "", "metadata": {}, "score": "59.167206"}
{"text": "32 , abstract 275 , supplement 3 , 2014 .View at Google Scholar . E. Vasile , N. de Lio , and C. Cappelli , \" Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "59.198105"}
{"text": "Georgoulias V , Ardavanis A , Agelidou A et al ( 2004 ) Docetaxel versus docetaxel plus cisplatin as front - line treatment of patients with advanced non - small - cell lung cancer : a randomized , multicenter phase III trial .", "label": "", "metadata": {}, "score": "59.414314"}
{"text": "These results establish gemcitabine plus nab - paclitaxel as a new standard treatment option for patients with metastatic pancreatic cancer .In September , based on the findings of this study , the FDA approved nab - paclitaxel for treatment of patients with metastatic pancreatic cancer .", "label": "", "metadata": {}, "score": "59.46355"}
{"text": "101 , no .6 , pp .908 - 915 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Oettle , S. Post , P. Neuhaus et al . , \" Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative - intent resection of pancreatic cancer : a randomized controlled trial , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "59.569824"}
{"text": "Patients will be followed up for at least 12 months .Ethics issue .The study has been approved by the ethics committee of The First Affiliated Hospital of Third Military Medical University ( No : KY201006 ) , and is registered at ChiCTR ( Chinese Clinical Trial Registry , trial Identifier ChiCTR - TRC-12602105 ) .", "label": "", "metadata": {}, "score": "59.716774"}
{"text": "[ 16 , 17 ] .Not one of these phase III trials has demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first - line treatment of metastatic pancreatic cancer .", "label": "", "metadata": {}, "score": "59.72693"}
{"text": "Similar results were reported by Peddi et al .[ 18 ] in a multi - institutional registry study .Among 23 patients with BRPC and LAPC a 34 % response rate was observed , with an 84 % disease control rate , in spite of dose reductions .", "label": "", "metadata": {}, "score": "59.749508"}
{"text": "Moertel CG , Kvols LK , O'Connell MJ and Rubin J : Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin .Evidence of major therapeutic activity in the anaplastic variants of these neoplasms .", "label": "", "metadata": {}, "score": "59.7565"}
{"text": "5 , pp .497 - 501 , 2012 .View at Google Scholar \u00b7 View at Scopus .M. A. Blazer , C. Wu , and R. Goldberg , \" Tolerability and efficacy of modified FOLFIRINOX (", "label": "", "metadata": {}, "score": "59.81953"}
{"text": "Vaughn DJ , Malkowicz SB , Zoltick B , et al .: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium : an active and tolerable outpatient regimen .", "label": "", "metadata": {}, "score": "59.845276"}
{"text": "In the study , conducted in Japan , patients were randomly assigned to receive gemcitabine or S-1 after surgery .Patients who received S-1 had a 44 % lower risk of dying compared with patients treated with gemcitabine .", "label": "", "metadata": {}, "score": "59.885197"}
{"text": "Over half of patients with NSCLC present with regional lymphatic and/or distant metastasis ( stage IIIB and IV ) at time of diagnosis , highlighting the need for new strategies to improve the prognosis of this disease [ 7 ] .", "label": "", "metadata": {}, "score": "59.890903"}
{"text": "Even immunotherapeutic approaches are considered as neoadjuvant therapies .A phase II study of neoadjuvant chemotherapy ( gemcitabine and fluorouracil ) with and without immunotherapy to CA125 ( Oregovomab ) followed by hypofractionated stereotactic radiotherapy and concurrent HIV protease inhibitor Nelfinavir is in course in patients with locally advanced pancreatic cancer ( NCT01959672 ) .", "label": "", "metadata": {}, "score": "59.905586"}
{"text": "Patients who had early - stage synchronous endometrial cancer were also eligible , provided there was no more than minimum invasion without high - gradefeatures .", "label": "", "metadata": {}, "score": "59.98546"}
{"text": "Each arm included eight cycles of triplet or sequential - doubletchemotherapy , whichprovidedaminimumoffourcycles that incorporated experimental treatments while maintaining at least four cycleswithcarboplatinandpaclitaxel .However , GCIG - basedinternationalcriteriafordeterminationofprogressionthatused serial measurements of serum CA-125 were permitted , which allowed initia- tionofsecondarytherapiesbeforelarge - volumeorsymptomaticrecurrence.5 Regimen Selection Dose and schedule were designed to maximize delivery of newer agents while preserving exposure to carboplatin and paclitaxel and equilibrating the risk of hematologic toxicity .", "label": "", "metadata": {}, "score": "60.029953"}
{"text": "One hundred twenty - five ( 78 % ) patients completed the restaging , 79 ( 63 % of 125 ) patients proceeded to surgery , and 66 ( 53 % of 125 ) patients received pancreaticoduodenectomy .", "label": "", "metadata": {}, "score": "60.06919"}
{"text": "Future studies to investigate gemcitabine in this setting are warranted .INTRODUCTION .Pancreatic neuroendocrine tumors ( pNETs ) account for 3 to 5 % of pancreatic malignancies with an incidence of around 1,000 cases per year in the United States [ 1].", "label": "", "metadata": {}, "score": "60.128635"}
{"text": "Cancer 85 ( 6 ) : 1261 - 8 , 1999 .Moore MJ , Goldstein D , Hamm J , et al .: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group .", "label": "", "metadata": {}, "score": "60.143593"}
{"text": "10 , pp .649 - 657 , 2012 .View at Google Scholar .J. P. Neoptolemos , D. D. Stocken , H. Friess et al . , \" A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "60.193634"}
{"text": "The International Collaborative Ovarian Neo- plasm ( ICON ) Group .Paclitaxel plus carboplatin ver- sus standard chemotherapy with either single - agent carboplatin or cyclophosphamide , doxorubicin , and cisplatin in women with ovarian cancer : The ICON3 randomised trial .", "label": "", "metadata": {}, "score": "60.290707"}
{"text": "A retrospective analysis of genetic changes in tumors of patients with metastatic colorectal cancer identifies new mutations that predict lack of response to the targeted drug panitumumab .", "label": "", "metadata": {}, "score": "60.30294"}
{"text": "[ 8 ] .Surgery .Complete resection can yield 5-year survival rates of 18 % to 24 % , but ultimate control remains poor because of the high incidence of both local and distant tumor recurrence .", "label": "", "metadata": {}, "score": "60.323143"}
{"text": "She was followed with a CT scan every two months and the imaging at eighth month from the start of chemotherapy showed progressive disease with new liver metastases and prominent peritoneal studding .", "label": "", "metadata": {}, "score": "60.378304"}
{"text": "20 ] [ Level of evidence : 1iiA ] Patients who received adjuvant gemcitabine or any other chemotherapy were excluded .Nab - paclitaxel / gemcitabine was more toxic than gemcitabine .", "label": "", "metadata": {}, "score": "60.463974"}
{"text": "Among the 19 patients treated with the FOLFIRI regimen , 6 ( 31.6 % ) had objective response , 6 ( 31.6 % ) had stable disease , and 7 ( 36.8 % ) had disease progression .", "label": "", "metadata": {}, "score": "60.479515"}
{"text": "A study by Welin et al .[ 22 ] showed that temozolomide alone or in combination with capecitabine and bevacizumab resulted in objective response or stabilization in 71 % of pNET patients who failed on first - line chemotherapy .", "label": "", "metadata": {}, "score": "60.511784"}
{"text": "Noda K , Nishiwaki Y , Kawahara M , Negoro S , Sugiura T , Yokoyama A , Fukuoka M , Mori K , Watanabe K and Tamura T : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small - cell lung cancer .", "label": "", "metadata": {}, "score": "60.59761"}
{"text": "Randomized Studies in Stage III Pancreatic Cancer : Median Survival .Three trials attempted to look at combined modality therapy versus radiation therapy alone .[ 5 , 6 , 7 ] The trials had substantial deficiencies in design or analysis .", "label": "", "metadata": {}, "score": "60.686256"}
{"text": "[ 10 ] [ Level of evidence : 1iiA ] .Nonetheless , the survival benefit persisted in a per - protocol analysis of patients receiving at least 75 % of planned therapy .", "label": "", "metadata": {}, "score": "60.690292"}
{"text": "1201 - 1208 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Patel , S. Hoffe , M. Malafa et al . , \" Neoadjuvant GTX Chemotherapy and IMRT - based chemoradiation for borderline resectable pancreatic cancer , \" Journal of Surgical Oncology , vol .", "label": "", "metadata": {}, "score": "60.705933"}
{"text": "A CT scan at the end of the fourth month showed progressive disease with new liver metastases , bone lesions and mediastinal lymph nodes .He was treated with FOLFIRI ( irinotecan , 5-fluorouracil and leucovorin ) .", "label": "", "metadata": {}, "score": "60.72335"}
{"text": "Clinically important ( A ) hematologic and ( B ) nonhematologic toxicities .A Pearson ?2test to assess the null hypothesis ( ie , the probability of adverse events is independent of treatment ) was statistically significant at P ?", "label": "", "metadata": {}, "score": "60.725178"}
{"text": "Several clinical studies [ 12 - 17 ] recently indicated that the efficacy of liposomal paclitaxel equaled or slightly exceeded that of the current paclitaxel ( Taxol \u00ae ) formulation , while having a superior safety profile .", "label": "", "metadata": {}, "score": "60.7517"}
{"text": "Scarfone G , Scambia G , Raspagliesi F , et al : A multicenter , randomized , phase III study comparing paclitaxel / carboplatin ( PC ) versus topotecan / pacli- taxel / carboplatin ( TPC ) in patients with stage III ( residual tumor ? 1 cm after primary surgery ) and IV ovarian cancer ( OC ) .", "label": "", "metadata": {}, "score": "60.75242"}
{"text": "Lilenbaum RC , Herndon JE 2nd , List MA et al ( 2005 ) Single - agent versus combination chemotherapy in advanced non - small - cell lung cancer : the cancer and leukemia group B ( study 9730 ) .", "label": "", "metadata": {}, "score": "60.770935"}
{"text": "Oettle H , Post S , Neuhaus P , et al .: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative - intent resection of pancreatic cancer : a randomized controlled trial .", "label": "", "metadata": {}, "score": "61.02935"}
{"text": "Peritoneal cytology .In a case series of 228 patients , positive peritoneal cytology had a positive predictive value of 94 % , specificity of 98 % , and sensitivity of 25 % for determining unresectability .", "label": "", "metadata": {}, "score": "61.04718"}
{"text": "Gatzemeier U , Pluzanska A , Szczesna A et al ( 2007 ) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non - small - cell lung cancer : the Tarceva Lung Cancer Investigation Trial .", "label": "", "metadata": {}, "score": "61.09243"}
{"text": "An earlier study showed that a drug called octreotide LAR substantially prolongs time to disease progression in patients with metastatic midgut neuroendocrine tumors .This year , researchers reported longer - term follow - up data from that same clinical trial , finding that octreotide LAR also extends overall survival in a subset of patients . 1 Between 2001 and 2008 , 85 patients were randomly assigned to receive octreotide LAR or placebo .", "label": "", "metadata": {}, "score": "61.10531"}
{"text": "Langer CJ , Manola J , Bernardo P et al ( 2002 ) Cisplatin - based therapy for elderly patients with advanced non - small - cell lung cancer : implications of Eastern Cooperative Oncology Group 5592 , a randomized trial .", "label": "", "metadata": {}, "score": "61.152115"}
{"text": "J Clin Oncol .Kulke MH , Kim H , Clark JW , Enzinger PC , Lynch TJ , Morgan JA , Vincitore M , Michelini A and Fuchs CS : A Phase II trial of gemcitabine for metastatic neuroendocrine tumors .", "label": "", "metadata": {}, "score": "61.16851"}
{"text": "He achieved a partial response that persisted for a total of six months .A CT scan at the end of sixth months showed progressive disease with liver metastases .", "label": "", "metadata": {}, "score": "61.181572"}
{"text": "PubMed View Article .Schiller JH , Harrington D , Belani CP , Langer C , Sandler A , Krook J , Zhu J , Johnson DH : Comparison of four chemotherapy regimens for advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "61.213303"}
{"text": "They reported stable disease in 65 % of the patients and the median overall survival was less than one year .Gemcitabine was well tolerated .", "label": "", "metadata": {}, "score": "61.227425"}
{"text": "Feliu J , L\u00f3pez Alvarez MP , Jaraiz MA , et al .: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma .", "label": "", "metadata": {}, "score": "61.32422"}
{"text": "General information about clinical trials is also available from the NCI Web site .References : .Iacobuzio - Donahue CA , Fu B , Yachida S , et al .", "label": "", "metadata": {}, "score": "61.3305"}
{"text": "GOG 146-P -Phase II Evaluation of Cetuximab Combination with Carboplatin in the Treatment of Recurrent Platinum - Sensitive Ovarian or Primary Peritoneal Cancer .", "label": "", "metadata": {}, "score": "61.35061"}
{"text": ": Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma .Cancer 115 ( 12 ) : 2652 - 9 , 2009 .", "label": "", "metadata": {}, "score": "61.382957"}
{"text": "Hence , identification of alternative treatments for these patients should be considered a priority .Liposomal paclitaxel is a new formulation composed of paclitaxel and liposomes , with favorable pharmacokinetic properties .", "label": "", "metadata": {}, "score": "61.39276"}
{"text": "Of patients with grade 3 peripheral neuropathy , 44 % were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event .", "label": "", "metadata": {}, "score": "61.47857"}
{"text": "4 , Article ID e1000267 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Conroy , F. Desseigne , M. Ychou , et al . , \" FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "61.482227"}
{"text": "PubMed .Zeng SY , Li L , Zhong ML , Jiang W , Wu YY , Liu Y : [ A randomized controlled trial of two chemotherapy regimens ( paclitaxel liposome combined with platinum and paclitaxel combined with platinum ) in concurrent chemoradiotherapy for cervical carcinoma].", "label": "", "metadata": {}, "score": "61.587326"}
{"text": "Several less nephrotoxic regimens have been studied in clinical trials , but most of these trials have not focused on patients with renal impairment or poor performance status .", "label": "", "metadata": {}, "score": "61.663795"}
{"text": "Palliative chemotherapy beyond three courses conveys no survival or consistent quality - of - life benefits in advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "61.685925"}
{"text": "108 - 113 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Gillen , T. Schuster , C. M. Z. B\u00fcschenfelde , H. Friess , and J. Kleeff , \" Preoperative / neoadjuvant therapy in pancreatic cancer : A systematic review and meta - analysis of response and resection percentages , \" PLoS Medicine , vol .", "label": "", "metadata": {}, "score": "61.709003"}
{"text": "World J Gastroenterol .Brown DB , Gonsalves CF , Yeo CJ , Witkiewicz AK and Carr BI : One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin .", "label": "", "metadata": {}, "score": "61.79579"}
{"text": "We chose gemcitabine at 1,000 mg / m 2 on days 1 , 8 every 3 weeks due to history of neutropenia and thrombocytopenia with previous regimens .", "label": "", "metadata": {}, "score": "61.82344"}
{"text": "Anderson H , Hopwood P , Stephens RJ , et al ( 2000 ) Gemcitabine plus best supportive care ( BSC ) vs BSC in inoperable non - small cell lung cancer - a randomized trial with quality of life as the primary outcome .", "label": "", "metadata": {}, "score": "61.93804"}
{"text": "However , this is an exploratory analysis that can not control for potential unknown confounders .The EORTC / U. S. Gastrointestinal Intergroup RTOG-0848 phase III adjuvant trial evaluating the impact of chemoradiation after completion of a full course of gemcitabine with or without erlotinib is currently enrolling patients .", "label": "", "metadata": {}, "score": "61.969727"}
{"text": "Receipt of other anti - cancer treatment ( such as chemotherapy , radiotherapy , immunosuppressive agents , chemoembolization , or targeted agents ) .Recent ( 1 day to 4 weeks ) participation in another clinical drug trial .", "label": "", "metadata": {}, "score": "62.09895"}
{"text": "View at Google Scholar .P. J. Hosein , J. Macintyre , C. Kawamura et al . , \" A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline - resectable locally advanced pancreatic adenocarcinoma , \" BMC Cancer , vol .", "label": "", "metadata": {}, "score": "62.152943"}
{"text": "Evidence ( postoperative chemotherapy ) : .Charit\u00e9 Onkologie ( CONKO)-001 : Results have also been reported from CONKO-001 , a multicenter phase III trial of 368 patients with resected pancreatic cancer who were randomly assigned to receive six cycles of adjuvant gemcitabine versus observation .", "label": "", "metadata": {}, "score": "62.19011"}
{"text": "Nab - paclitaxel , an albumin bound formulation of paclitaxel particles , has recently been shown to be effective in the treatment of advanced pancreatic cancer .", "label": "", "metadata": {}, "score": "62.224876"}
{"text": "Rose PG , Greer BE , Horowitz IR , et al : Pacli- taxel , carboplatin and pegylated liposomal doxorubi- cin in ovarian and peritoneal carcinoma : A phase I study of the Gynecologic Oncology Group .", "label": "", "metadata": {}, "score": "62.285347"}
{"text": "6 , pp .1253 - 1259 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. P. Zhu , J. Shi , Y. X. Chen , W. Xie , and Y. Lin , \" Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer : a meta - analysis , \" Radiotherapy and Oncology , vol .", "label": "", "metadata": {}, "score": "62.413765"}
{"text": "There was increased hematologic toxicity in the triplet regi- mens and increased thrombocytopenia in both arms with gemcit- abine ( Fig 2A ) .Neuropathy was decreased in the doublet regimens ( Fig 2B ) , which included only four cycles of paclitaxel .", "label": "", "metadata": {}, "score": "62.47791"}
{"text": "Based on the strength of the available evidence , treatment options may be described as either \" standard \" or \" under clinical evaluation .\" These classifications should not be used as a basis for insurance reimbursement determinations .", "label": "", "metadata": {}, "score": "62.49053"}
{"text": "Line Chemotherapy .GOG 212 -Randomized Phase III Trial of Maintenance chemotherapy Comparing 12 , Monthly Cycles of Single Agent Paclitaxel or Xyotax vs. No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum / Taxane Chemotherapy .", "label": "", "metadata": {}, "score": "62.542557"}
{"text": "At the end of the sixth month , the patient progressed with worsening liver metastases and declined in performance status .The patient was placed on hospice and died after 49 days .", "label": "", "metadata": {}, "score": "62.787243"}
{"text": "Ciuleanu TE , Brodowicz T , Belani CP , et al ( 2008 ) Maintenance pemetrexed plus best supportive care ( BSC ) versus placebo plus BSC : a phase III study .", "label": "", "metadata": {}, "score": "62.95125"}
{"text": "Assess the value of tumor parameters as prognostic factors for initial tumor response and recurrence - free survival in this patient population .Four weeks after induction therapy , patients undergo urologic evaluation .", "label": "", "metadata": {}, "score": "62.954674"}
{"text": "One randomized study demonstrated the superiority of 5-fluorouracil ( 5-FU ) based CRT compared with best supportive care .Most studies used 5-FU or gemcitabine as reference chemotherapy in combination with radiation doses of 50 - 60 Gy .", "label": "", "metadata": {}, "score": "62.955708"}
{"text": "J Clin Oncol 2003 , 21 : 3207 - 3213 .PubMed View Article .Fisher MD , D'Orazio A : Phase II and III trials : comparison of four chemotherapy regimens in advanced non small - cell lung cancer ( ECOG 1594 ) .", "label": "", "metadata": {}, "score": "62.972485"}
{"text": "The patient received 1,000 mg / m 2 gemcitabine on days 1 , 8 and 15 every 4 weeks .After two cycles of gemcitabine ( 8 weeks ) , a CT scan of her abdomen showed minor response ( overall 22 % shrinkage ) .", "label": "", "metadata": {}, "score": "63.046234"}
{"text": "LBA7516 ) .Soon Y , Stockler MR , Boyer M , Askie L ( 2008 ) Duration of chemotherapy for advanced non - small cell lung cancer : an updated systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "63.123093"}
{"text": "Advances .Octreotide LAR prolongs overall survival in some patients with a rare form of GI cancer .Neuroendocrine tumors begin in the hormone - producing cells of the body 's neuroendocrine system .", "label": "", "metadata": {}, "score": "63.190506"}
{"text": "Cancer 52 ( 9 ) : 1577 - 82 , 1983 .DeCaprio JA , Mayer RJ , Gonin R , et al .: Fluorouracil and high - dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas : results of a phase II trial .", "label": "", "metadata": {}, "score": "63.341396"}
{"text": "After sequential chemotherapy 3 patients ( 37 % ) underwent radical surgical resection .Notably , all resected tumours showed signs of tumour regression with one patient showing a complete pathological response .", "label": "", "metadata": {}, "score": "63.368965"}
{"text": "If the WBCC falls within the range of 2.0 to 3.0 \u00d7 10 9 /l , chemotherapy will be stopped until the WBCC increases to 3.0 \u00d7 10 9 /l , or above .", "label": "", "metadata": {}, "score": "63.394527"}
{"text": "In this analysis , BRAF gene mutations were not associated with patient survival .These findings suggest that patients should be tested for both KRAS and NRAS mutations before receiving panitumumab to avoid the adverse effects and costs of a potentially ineffective treatment .", "label": "", "metadata": {}, "score": "63.41219"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable . \"Despite the high initial response rate , up to 80 % of patients will recur and eventually develop resistance to therapy , which leads to incurable disease [ 3].", "label": "", "metadata": {}, "score": "63.45422"}
{"text": "Palliative therapy .Chemotherapy : gemcitabine ; gemcitabine and erlotinib ; or oxaliplatin , irinotecan , leucovorin , and fluorouracil ( 5-FU ) ( FOLFIRINOX ) .", "label": "", "metadata": {}, "score": "63.469505"}
{"text": "Cisplatin - based doublet chemotherapy is recommended as the first - line treatment for patients with advanced NSCLC .We have designed a trial to assess whether first - line chemotherapy using liposomal paclitaxel combined with cisplatin ( LP regimen ) is superior to gemcitabine combined with cisplatin ( GP regimen ) in efficacy ( both short - term and long - term efficacy ) and safety ( adverse events ; AEs ) .", "label": "", "metadata": {}, "score": "63.49666"}
{"text": "More recently , results of a retrospective analysis conducted on 43 patients with BRPC and LAPC treated with a modified FOLFIRINOX regime have been presented [ 19 ] .", "label": "", "metadata": {}, "score": "63.506924"}
{"text": "A 4 % response rate was observed in patients treated with combination chemotherapy while no objective response was seen in patients treated with gemcitabine alone .", "label": "", "metadata": {}, "score": "63.55246"}
{"text": "Efficacy will be evaluated every two cycles , with chest CT performed 4 weeks after each evaluation to confirm if the result is CR or PR .", "label": "", "metadata": {}, "score": "63.552475"}
{"text": "Bookman MA , McMeekin DS , Fracasso PM : Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer : A phase I study of the Gynecologic Oncology Group .", "label": "", "metadata": {}, "score": "63.60404"}
{"text": "Sederholm C , Hillerdal G , Lamberg K et al ( 2005 ) Phase III trial of gemcitabine plus carboplatin versus single - agent gemcitabine in the treatment of locally advanced or metastatic non - small - cell lung cancer : the Swedish Lung Cancer Study Group .", "label": "", "metadata": {}, "score": "63.630367"}
{"text": "During the last two decades , several studies have evaluated the role of neoadjuvant chemotherapy , radiotherapy , or combination of both in resectable pancreatic cancer .", "label": "", "metadata": {}, "score": "63.70078"}
{"text": "J Clin Oncol 26:294s , 2008 ( suppl ; abstr LBA5505 ) 32 .Burger RA , Sill M , Monk BJ , et al : Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer : A Gy- necologic Oncology Group Study .", "label": "", "metadata": {}, "score": "63.72721"}
{"text": "Eur J Cancer 36 ( 8) : 1016 - 25 , 2000 .Bramhall SR , Rosemurgy A , Brown PD , et al .: Marimastat as first - line therapy for patients with unresectable pancreatic cancer : a randomized trial .", "label": "", "metadata": {}, "score": "63.744514"}
{"text": "The median progression - free survival and OS were 10.48 months and 15.64 months , respectively .Stokes et al .[ 27 ] also prospectively examined 40 borderline resectable pancreatic cancer patients treated with combined capecitabine - based chemoradiation .", "label": "", "metadata": {}, "score": "63.756645"}
{"text": "The goals of the group are to promote excellence in the quality and integrity of clinical trials in gynecologic malignancies .The Milton S. Hershey Medical Center is one of 48 \" parent \" institutions with over 200 affiliate institutions in the United States .", "label": "", "metadata": {}, "score": "63.82596"}
{"text": "First enrollment date Total No .Includes patients enrolled from the following : Eastern Cooperative Oncology Group ( ECOG ; n ? 24 ) , North Central Cancer Treatment Group ( NCCTG ; n ? 23 ) , Cancer and Leukemia Group B ( CALGB ; n ? 12 ) , National Surgical Adjuvant Breast and Bowel Project ( NSABP ; n ? 1 ) , Radiation Therapy Oncology Group ( RTOG ; n ? 1 ) , Southwest Oncology Group ( SWOG ; n ? 1 ) , and Other ( n ?", "label": "", "metadata": {}, "score": "63.88399"}
{"text": "Postoperative chemotherapy with gemcitabine provides a modest but significant survival benefit with a median OS of 23 months compared to about 20 months in patients undergoing resection alone and a 5-year survival rate of 21 % versus 9 % [ 3 ] .", "label": "", "metadata": {}, "score": "63.93521"}
{"text": "Greer BE , Bundy BN , Ozols RF , et al : Implica- tions of second - look laparotomy in the context of optimally resected stage III ovarian cancer : A non-", "label": "", "metadata": {}, "score": "63.964767"}
{"text": "Neoptolemos JP , Stocken DD , Bassi C , et al .: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial .", "label": "", "metadata": {}, "score": "63.96515"}
{"text": "Ansell SM , Mahoney MR , Green EM and Rubin J : Topotecan in patients with advanced neuroendocrine tumors : a phase II study with significant hematologic toxicity .", "label": "", "metadata": {}, "score": "64.02192"}
{"text": "References : .Cullinan SA , Moertel CG , Fleming TR , et al .: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma .", "label": "", "metadata": {}, "score": "64.07886"}
{"text": "GOG 174 -Randomized Phase III Trial of Weekly Parenteral Methotrexate vs. Pulsed Dactinomycin as Primary Management of Low Risk Gestational Trophoblastic Neoplasia .Publisher main menu .", "label": "", "metadata": {}, "score": "64.13541"}
{"text": "Scagliotti GV , De Marinis F , Rinaldi M et al ( 2002 )Phase III randomized trial comparing three platinum - based doublets in advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "64.139465"}
{"text": ": Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer : a randomized trial .J Clin Oncol 15 ( 6 ) : 2403 - 13 , 1997 .", "label": "", "metadata": {}, "score": "64.14951"}
{"text": "JAMA 253 ( 14 ) : 2061 - 7 , 1985 .Rothenberg ML , Moore MJ , Cripps MC , et al .: A phase II trial of gemcitabine in patients with 5-FU - refractory pancreas cancer .", "label": "", "metadata": {}, "score": "64.18022"}
{"text": "Gastrointestinal Tumor Study Group ( GITSG)-9273 trial : Prior to 2000 , several phase III trials evaluated combined modality therapy versus radiation therapy alone .[", "label": "", "metadata": {}, "score": "64.28136"}
{"text": "One study reported that the hormonal drug octreotide improves survival for some patients with advanced midgut neuroendocrine tumors , a rare form of GI cancer .", "label": "", "metadata": {}, "score": "64.350136"}
{"text": "Indeed , most of the trials are single phase II studies .The administration of radiation therapy before surgery has some advantages compared to the postoperative setting and in particular it allows radiation to be delivered to well oxygenated cells before surgical devascularization .", "label": "", "metadata": {}, "score": "64.36655"}
{"text": "20 ] [ Level of evidence : 1iiDii ] In contrast to the previous trials , the primary endpoint was disease - free survival ( DFS ) .", "label": "", "metadata": {}, "score": "64.41958"}
{"text": "Fj\u00e4llskog ML , Granberg DP , Welin SL , Eriksson C , Oberg KE , Janson ET and Eriksson BK : Treatment with cisplatin and etoposide in patients with neuroendocrine tumors .", "label": "", "metadata": {}, "score": "64.47761"}
{"text": "This study establishes capecitabine and bevacizumab as a standard maintenance therapy in colorectal cancer .Patients with colorectal cancer harboring NRAS mutations are unlikely to benefit from panitumumab .", "label": "", "metadata": {}, "score": "64.55719"}
{"text": "General information about clinical trials is also available from the NCI Web site .References : .Dalton RR , Sarr MG , van Heerden JA , et al .", "label": "", "metadata": {}, "score": "64.57984"}
{"text": "21 , pp .3496 - 3502 , 2008 .View at Publisher \u00b7 View at Google Scholar .G. R. Varadhachary , R. A. Wolff , C. H. Crane et al . , \" Preoperative gemcitabine and cisplatin followed by gemcitabine - based chemoradiation for resectable adenocarcinoma of the pancreatic head , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "64.59047"}
{"text": "Cancer 89 ( 8) : 1706 - 13 , 2000 .Rocha Lima CM , Savarese D , Bruckner H , et al .: Irinotecan plus gemcitabine induces both radiographic and CA 19 - 9 tumor marker responses in patients with previously untreated advanced pancreatic cancer .", "label": "", "metadata": {}, "score": "64.60051"}
{"text": "Gefitinib in combination with paclitaxel and carboplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 2 .J Clin Oncol 22(5):785 - 794 PubMed CrossRef .", "label": "", "metadata": {}, "score": "64.623146"}
{"text": "J Clin Oncol 24:1127 - 1135 , 2006 29 .Kristensen GB , Vergote I , Stuart G , et al : First - line treatment of ovarian cancer FIGO stages IIb - IV with paclitaxel / epirubicin / carboplatin versus paclitaxel / carboplatin .", "label": "", "metadata": {}, "score": "64.64964"}
{"text": "One hundred and forty - five consecutive pancreaticoduodenectomies without mortality .Ann Surg 217 ( 5 ) : 430 - 5 ; discussion 435 - 8 , 1993 .", "label": "", "metadata": {}, "score": "64.65038"}
{"text": "15 , pp .3509 - 3516 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. M. R. Lima , M. R. Green , R. Rotche et al . , \" Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "64.721664"}
{"text": "du Bois A , Belau A , Wagner U , et al : A phase II study of paclitaxel , carboplatin , and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC - IV ( AGO - OVAR protocol OVAR-8 ) .", "label": "", "metadata": {}, "score": "64.757126"}
{"text": "In group II , patients with arterial involvement and/or venous involvement receive 6 cycles of GTX , then GX / RT and then surgery ( NCT01065870 ) .", "label": "", "metadata": {}, "score": "64.76633"}
{"text": "Importantly , the 66 patients who completed the whole therapy including surgery had a significantly better clinical outcome ( median OS of 40 months and a 5-year survival rate of 36 % ) compared to a median survival of 13 months in the remaining 94 unresected patients .", "label": "", "metadata": {}, "score": "64.78482"}
{"text": "Chemoradiation followed by chemotherapy .Chemotherapy followed by chemoradiation , for patients without metastatic disease .Chemotherapy : gemcitabine ; gemcitabine and erlotinib ; gemcitabine and nab - paclitaxel ; or 5-fluorouracil ( 5-FU ) , leucovorin , irinotecan , and oxaliplatin ( FOLFIRINOX ) .", "label": "", "metadata": {}, "score": "64.870316"}
{"text": "Finally , a phase II / III nonrandomized study has been designed to assess the safety and benefit of 6 cycles of chemotherapy treatment consisting of gemcitabine , capecitabine , and docetaxel ( also called \" GTX \" ) .", "label": "", "metadata": {}, "score": "64.88269"}
{"text": "Hotta K , Matsuo K , Ueoka H , Kiura K , Tabata M , Tanimoto M ( 2004 )Addition of platinum compounds to a new agent in patients with advanced non - small - cell lung cancer : a literature based meta - analysis of randomised trials .", "label": "", "metadata": {}, "score": "64.90872"}
{"text": "[ 18 ] [ Level of evidence : 1iiA ] The primary endpoints were OS for all patients and OS for patients with pancreatic head tumors .", "label": "", "metadata": {}, "score": "64.920654"}
{"text": "In particular , thenumberanddiversityofnewagentsidentifyimportant challenges to our conventional clinical paradigm .Compelling data havealsoemergedwithsingle - agentbevacizumabinrecurrentdisease , which prompted the development of two international , front - line , phaseIIItrialstoaddresstheadditionofbevacizumabincombination withcarboplatinandpaclitaxel.32 Large , multiarm , multistage , phase III trials are feasible with international collaboration and can promote the optimal use of lim- ited clinical resources .", "label": "", "metadata": {}, "score": "64.96155"}
{"text": "Gastrointestinal toxicity required hospitalization in 9 patients ( 32 % ) but no patients experienced a delay in surgery .A total of 23 patients without evidence of progressive disease underwent laparotomy and 17 patients ( 61 % ) a radical pancreatoduodenectomy .", "label": "", "metadata": {}, "score": "65.00262"}
{"text": "Neoptolemos JP , Stocken DD , Friess H , et al .: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer .", "label": "", "metadata": {}, "score": "65.05403"}
{"text": "All patients will be followed up for at least 12 months .Reporting of adverse events .Participants will be requested to report any AEs occurring at any point throughout the whole trial , and the doctors will give appropriate advice .", "label": "", "metadata": {}, "score": "65.074036"}
{"text": "The benefit of neoadjuvant therapies in BRPC was retrospectively reviewed by Katz et al .[ 24 ] at MDACC .Restaging CT scan was repeated every 2 months during the treatment and 4 to 6 weeks after completion to determine resectability .", "label": "", "metadata": {}, "score": "65.143906"}
{"text": "17 , pp .2855 - 2862 , 2009 .View at Publisher \u00b7 View at Google Scholar .P. Sukharamwala , J. Thoens , M. Szuchmacher , et al . , \" Advanced age is a risk factor for post - operative complications and mortality after a pancreaticoduodenectomy : a meta - analysis and systematic review , \" HPB , vol .", "label": "", "metadata": {}, "score": "65.38768"}
{"text": "du Bois A , Luck HJ , Meier W , et al : Arbeits- gemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group : A randomized clinical trial of cisplatin / paclitaxel versus carboplatin / paclitaxel as first - line treatment of ovarian cancer .", "label": "", "metadata": {}, "score": "65.3886"}
{"text": "Most of the studies investigating the efficacy of gemcitabine - based chemotherapy in advanced pancreatic cancer included a percentage of LAPC patients .Gemcitabine - based combinations have proved to induce higher response rate ( about 26 % ) compared to single agent gemcitabine ( 4 - 15 % ) and response rates were similar to those observed in metastatic disease [ 29 , 30 ] .", "label": "", "metadata": {}, "score": "65.465706"}
{"text": "She continued temozolomide for approximately four months and then progressed with worsening liver metastases and ascites .The patient had ECOG performance status of 2 .", "label": "", "metadata": {}, "score": "65.47774"}
{"text": ": Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single - agent docetaxel .Urology 52 ( 1 ) : 56 - 60 , 1998 .", "label": "", "metadata": {}, "score": "65.51372"}
{"text": "[ 15 , 16 , 17 , 18 , 19 , 20 ] In general , outcomes of studies in patients unfit for cisplatin have been inferior to those of cisplatin - based regimens with reported median survival times of less than 1 year .", "label": "", "metadata": {}, "score": "65.54197"}
{"text": "Neoptolemos JP , Dunn JA , Stocken DD , et al .: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial .", "label": "", "metadata": {}, "score": "65.56897"}
{"text": "More than 10,000 women are projected to have participated in these interna- tional studies , and it would be surprising if small differences in dose or schedule would have a major impact on long - term clini- cal outcomes .", "label": "", "metadata": {}, "score": "65.59857"}
{"text": "Physical status , physical examination , routine blood and urine tests , liver and renal function tests , and ECG should be performed 2 to 3 days before each chemotherapy cycle .", "label": "", "metadata": {}, "score": "65.65892"}
{"text": "Mitry E , Baudin E , Ducreux M , Sabourin JC , Rufi\u00e9 P , Aparicio T , Aparicio T , Lasser P , Elias D and Duvillard P : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin .", "label": "", "metadata": {}, "score": "65.698395"}
{"text": "Finkelstein DM , Ettinger DS , Ruckdeschel JC ( 1986 )Long - term survivors in metastatic non - small - cell lung cancer : an Eastern Cooperative Oncology Group Study .", "label": "", "metadata": {}, "score": "65.729836"}
{"text": "Chemotherapy regimens in treatment arms were as follows : I , carboplatin ? paclitaxel ; II , carboplatin ? paclitaxel ? gemcitabine ; III , carboplatin ? paclitaxel ? doxorubicin ; IV , carboplatin ? topotecan then carboplatin ? paclitaxel ; V , carboplatin ? gemcitabine then carboplatin ? paclitaxel .", "label": "", "metadata": {}, "score": "65.78372"}
{"text": "PubMed View Article .Yan F , Li L , Deng Z , Jin Q , Zheng H : Paclitaxel - liposome loaded microbubbles for ultrasound - triggered drug delivery in vitro and in vivo .", "label": "", "metadata": {}, "score": "65.83013"}
{"text": "Gefitinib in combination with gemcitabine and cisplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 1 .J Clin Oncol 22(5):777 - 784 PubMed CrossRef .", "label": "", "metadata": {}, "score": "65.83303"}
{"text": "Eur J Cancer 37 ( 17 ) : 2212 - 5 , 2001 .De Santis M , Bellmunt J , Mead B , et al .", "label": "", "metadata": {}, "score": "65.90286"}
{"text": "In Japan and some other countries , S-1 has been approved to treat several cancers , including stomach , colorectal , pancreatic , biliary , head and neck , NSCLC , and metastatic breast cancers .", "label": "", "metadata": {}, "score": "65.939926"}
{"text": "J Clin Oncol 29 ( 31 ) : 4105 - 12 , 2011 .Cancer 48 ( 8) : 1705 - 10 , 1981 .Chauffert B , Mornex F , Bonnetain F , et al .", "label": "", "metadata": {}, "score": "65.947205"}
{"text": "Theaccrualratereached1,200patientsperyear , whichexceeded all prior combined accruals on GOG phase III trials in EOC .Strong participationwithinthegynecologiconcologycommunitysucceeded inenrollingapproximately6.25%ofallwomenwhohadnewlydiag- nosedadvanced - stagediseaseintheUnitedStatesduringthisperiod .Currently , therearenotsufficientdatatorecommendanynew two- or three - drug combination ; thus , carboplatin with paclitaxel remainsthestandardregimenofchoice .", "label": "", "metadata": {}, "score": "65.94838"}
{"text": "Treatment Options Under Clinical Evaluation for Recurrent Pancreatic Cancer .Treatment options under clinical evaluation include the following : .Phase I and II clinical trials evaluating pharmacologic modulation of fluorinated pyrimidines , new anticancer agents , or biological agents .", "label": "", "metadata": {}, "score": "65.99417"}
{"text": "Bamias A , Aravantinos G , Deliveliotis C , et al .: Docetaxel and cisplatin with granulocyte colony - stimulating factor ( G - CSF ) versus MVAC with G - CSF in advanced urothelial carcinoma : a multicenter , randomized , phase III study from the Hellenic Cooperative Oncology Group .", "label": "", "metadata": {}, "score": "66.039474"}
{"text": ": Combined modality program with possible organ preservation for invasive bladder carcinoma : results of RTOG protocol 85 - 12 .Int J Radiat Oncol Biol Phys 25 ( 5 ) : 783 - 90 , 1993 .", "label": "", "metadata": {}, "score": "66.10785"}
{"text": "Stathopoulos GP , Mavroudis D , Tsavaris N , et al .: Treatment of pancreatic cancer with a combination of docetaxel , gemcitabine and granulocyte colony - stimulating factor : a phase II study of the Greek Cooperative Group for Pancreatic Cancer .", "label": "", "metadata": {}, "score": "66.12975"}
{"text": "However , the pharmaceutical properties of the drugs or formulations , including poor drug permeability through cell membranes or tissue barriers , short circulating half - life , and rapid metabolism , heavily influence the effectiveness of tumor therapy [ 8 ] .", "label": "", "metadata": {}, "score": "66.228"}
{"text": "Storniolo AM , Enas NH , Brown CA , et al .: An investigational new drug treatment program for patients with gemcitabine : results for over 3000 patients with pancreatic carcinoma .", "label": "", "metadata": {}, "score": "66.26374"}
{"text": "[ Time Frame : From the start of protocol treatment to the date the last patient has completed treatment .Analysis occurs after all patients have completed treatment . ]", "label": "", "metadata": {}, "score": "66.2655"}
{"text": "General information about clinical trials is also available from the NCI Web site .References : .Rothenberg ML , Moore MJ , Cripps MC , et al .", "label": "", "metadata": {}, "score": "66.27139"}
{"text": "View at Google Scholar .M. H. G. Katz , R. Marsh , J. M. Herman et al . , \" Borderline resectable pancreatic cancer : need for standardization and methods for optimal clinical trial design , \" Annals of Surgical Oncology , pp . 1 - 9 , 2013 .", "label": "", "metadata": {}, "score": "66.286606"}
{"text": "[17 ] included 16 patients with LAPC treated with FOLFIRINOX .A response rate of 50 % was shown in LAPC patients ; interestingly , the authors modified the FOLFIRINOX regimen with dose reductions in 29 out of 35 patients starting from the first cycle .", "label": "", "metadata": {}, "score": "66.32894"}
{"text": "Abbreviations : GP , gemcitabine plus cisplatin ; IV , intravenous ; LP , liposomal paclitaxel . 1In the LP group , the liposomal paclitaxel must be used before cisplatin to avoid myelosuppression .", "label": "", "metadata": {}, "score": "66.34001"}
{"text": "The specific pharmaceutical properties of liposomal paclitaxel .Paclitaxel is a complex diterpenoid natural product , which has become a first - line treatment for NSCLC .", "label": "", "metadata": {}, "score": "66.37571"}
{"text": "Current Clinical Trials .Check for U.S. clinical trials from NCI 's list of cancer clinical trials that are now accepting patients with stage I pancreatic cancer and stage II pancreatic cancer .", "label": "", "metadata": {}, "score": "66.45279"}
{"text": "PubMed .Guo W , Johnson JL , Khan S , Ahmad A , Ahmad I : Paclitaxel quantification in mouse plasma and tissues containing liposome - entrapped paclitaxel by liquid chromatography - tandem mass spectrometry : application to a pharmacokinetics study .", "label": "", "metadata": {}, "score": "66.61113"}
{"text": "Cabanes A , Briggs KE , Gokhale PC , Treat JA , Rahman A : Comparative in vivo studies with paclitaxel and liposome - encapsulated paclitaxel .", "label": "", "metadata": {}, "score": "66.618225"}
{"text": ": Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma .J Am Coll Surg 188 ( 4 ) : 421 - 6 , 1999 .Willett CG , Daly WJ , Warshaw AL : CA 19 - 9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer .", "label": "", "metadata": {}, "score": "66.62809"}
{"text": "[ 22 , 23 ] .Current Clinical Trials .Check for U.S. clinical trials from NCI 's list of cancer clinical trials that are now accepting patients with stage III pancreatic cancer .", "label": "", "metadata": {}, "score": "66.76743"}
{"text": "The doses of chemotherapy drugs will be decreased by 25 % in the next cycle if IV degree toxicity ( including fever - induced neutropenia syndrome ) emerges .", "label": "", "metadata": {}, "score": "66.79289"}
{"text": "Many other doublet and singlet noncisplatin chemotherapy regimens , such as gemcitabine plus paclitaxel , have been studied in healthier subjects with advanced - stage urothelial carcinoma .", "label": "", "metadata": {}, "score": "66.80406"}
{"text": "Progression - free survival .Objective survival .Median survival time .Survival rate at 1 year .Time to disease progression .Toxicity .Follow - up will consist of a telephone survey and a visit to the clinic for re - examination .", "label": "", "metadata": {}, "score": "66.834854"}
{"text": ": Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation .The National Cancer Institute of Canada Clinical Trials Group .", "label": "", "metadata": {}, "score": "66.887535"}
{"text": "The corresponding median and 1-year survival rates for patients who received erlotinib versus placebo were 6.2 months and 5.9 months , and 23 % versus 17 % , respectively .", "label": "", "metadata": {}, "score": "66.96908"}
{"text": "[ 1 ] [ Level of evidence : 1iiA ] Therefore , investigators have struggled with the question of whether chemoradiation for patients presenting with stage III disease is warranted .", "label": "", "metadata": {}, "score": "67.00261"}
{"text": "Another randomized phase III study ( NEOPAC study , NCT01314027 ) is comparing adjuvant gemcitabine and neoadjuvant gemcitabine / oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer .", "label": "", "metadata": {}, "score": "67.044914"}
{"text": "Evaluate the safety and tolerability of induction chemoradiotherapy with paclitaxel and cisplatin followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy in patients with stage II or III muscle invasive carcinoma of the bladder previously treated with transurethral tumor resection .", "label": "", "metadata": {}, "score": "67.054085"}
{"text": "Iaffaioli RV , Tortoriello A , Facchini G , et al : Phase I / II study of gemcitabine and carboplatin in stages IIIB to IV non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "67.08658"}
{"text": "Frasci G , Lorusso V , Panza N et al ( 2000 ) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "67.18031"}
{"text": "All patients received prophylactic pegfilgrastim and rate of G3/4 hematological toxicities was remarkably low with no episode of febrile neutropenia or G3/4 thrombocytopenia .A similar chemotherapy combination , the FOLFOXIRI regimen , has been evaluated in an Italian phase II study in 32 patients with unresectable or borderline resectable PDAC patients .", "label": "", "metadata": {}, "score": "67.22366"}
{"text": "Muggia FM , Braly PS , Brady MF , et al : Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with sub- optimal stage III or IV ovarian cancer : A Gynecologic Oncology Group study .", "label": "", "metadata": {}, "score": "67.28648"}
{"text": "Ferlay J , Shin HR , Bray F , Forman D , Mathers C , Parkin DM : Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 .", "label": "", "metadata": {}, "score": "67.312836"}
{"text": "Furthermore , patients who completed neoadjuvant chemoradiation and did not progress at restaging had a higher chance of achieving R0 resection and a higher overall survival when compared to historical data .", "label": "", "metadata": {}, "score": "67.354645"}
{"text": "Presently , six studies are assessing the potential of FOLFIRINOX as neoadjuvant therapy for pancreatic cancer .Among them , a phase II trial has been designed with FOLFIRINOX ( 5-fluorouracil , irinotecan , oxaliplatin , and gemcitabine ) for six cycles prior to combined modality treatment with gemcitabine during and following IMRT ( NCT01661088 ) .", "label": "", "metadata": {}, "score": "67.358505"}
{"text": "Burris HA 3rd , Moore MJ , Andersen J , et al .: Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer : a randomized trial .", "label": "", "metadata": {}, "score": "67.36883"}
{"text": "Saif MW , Kaley K , Penney R , Hotchkiss S , Syrigos KN and Strimpakos AS : The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer ( CRC ) : a single institution experience .", "label": "", "metadata": {}, "score": "67.39062"}
{"text": "Royston P , Parmar MKB , Qian W : Novel de- signs for multi - arm clinical trials with survival out- comes with an application in ovarian cancer .", "label": "", "metadata": {}, "score": "67.39925"}
{"text": "D'Addario G , Pintilie M , Leighl NB , Feld R , Cerny T , Shepherd FA ( 2005 ) Platinum - based versus non - platinum - based chemotherapy in advanced non - small - cell lung cancer : a meta - analysis of the published literature .", "label": "", "metadata": {}, "score": "67.414276"}
{"text": "He continued FOLFIRI for a total of six months and then developed lung metastases .His ECOG performance status was 2 and gemcitabine was administered .", "label": "", "metadata": {}, "score": "67.4442"}
{"text": "Arch Surg 120 ( 8) : 899 - 903 , 1985 .Klinkenbijl JH , Jeekel J , Sahmoud T , et al .: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group .", "label": "", "metadata": {}, "score": "67.54186"}
{"text": "Evidence ( chemotherapy ) : . [ 15 ] [ Level of evidence : 1iiA ] .Gemcitabine alone versus gemcitabine and erlotinib : The National Cancer Institute of Canada performed a phase III trial ( CAN - NCIC - PA3 [ NCT00026338 ] ) that compared gemcitabine alone versus the combination of gemcitabine and erlotinib ( 100 mg / day ) in patients with advanced or metastatic pancreatic carcinomas .", "label": "", "metadata": {}, "score": "67.55335"}
{"text": "The study was stopped early when the chemoradiation therapy arms were found to have better efficacy .The 1-year survival was 11 % for patients who received EBRT alone compared with 38 % for patients who received chemoradiation therapy with 40 Gy and 36 % for patients who received chemoradiation therapy with 60 Gy .", "label": "", "metadata": {}, "score": "67.569695"}
{"text": "Eur J Cancer 47 ( 11 ) : 1676 - 81 , 2011 .Tepper JE , Noyes D , Krall JM , et al .", "label": "", "metadata": {}, "score": "67.614"}
{"text": "Helsing M , Bergman B , Thaning L , Hero U ( 1998 ) Quality of life and survival in patients with advanced non - small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only .", "label": "", "metadata": {}, "score": "67.65451"}
{"text": "The median survival duration is 5 months in the patients with poorly differentiated pNET with the presence of distant metastases and our patients clearly lived longer by the addition of more chemotherapeutic agents to their treatment : the overall survival was 15.9 , 17.5 and 19 months , respectively .", "label": "", "metadata": {}, "score": "67.679"}
{"text": "After treatment , participants will be required to return to our department for follow - up every 4 months , at which time repeat chest CT will be performed .", "label": "", "metadata": {}, "score": "67.68532"}
{"text": "NCCN guidelines , \" Pancreatic adenocarcinoma , \" version 2 , 2012 .M. H. G. Katz , P. W. T. Pisters , D. B. Evans et al . , \" Borderline resectable pancreatic cancer : the importance of this emerging stage of disease , \" Journal of the American College of Surgeons , vol .", "label": "", "metadata": {}, "score": "67.69345"}
{"text": ": Paclitaxel in advanced urothelial carcinoma : its role in patients with renal insufficiency and as salvage therapy .J Urol 156 ( 5 ) : 1606 - 8 , 1996 .", "label": "", "metadata": {}, "score": "67.81171"}
{"text": "Jahnson S , Pedersen J , Westman G : Bladder carcinoma -- a 20-year review of radical irradiation therapy .Radiother Oncol 22 ( 2 ) : 111 - 7 , 1991 .", "label": "", "metadata": {}, "score": "67.84926"}
{"text": ": Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s .J Am Coll Surg 188 ( 6 ) : 658 - 66 ; discussion 666 - 9 , 1999 .", "label": "", "metadata": {}, "score": "67.89773"}
{"text": "Although , cytoreductive procedures are generally not recommended , transcatheter arterial chemoembolization or transarterial chemoembolization ( TACE ) may be indicated in selected patients .Systemic chemotherapy is the main stay for patients with systemic disease .", "label": "", "metadata": {}, "score": "68.003845"}
{"text": "Joint Lung Cancer Study Group .Eur J Cancer 34(7):1036 - 1044 PubMed CrossRef .Cullen MH , Billingham LJ , Woodroffe CM et al ( 1999 ) Mitomycin , ifosfamide , and cisplatin in unresectable non - small - cell lung cancer : effects on survival and quality of life .", "label": "", "metadata": {}, "score": "68.16722"}
{"text": "Pa- tients were also required to have a GOG performance status of ? 2 ; absolute neutrophil count ?L , platelets ?L , creatinine ? institutional upper limit normal ( ULN ) , bilirubin ?", "label": "", "metadata": {}, "score": "68.21706"}
{"text": "PubMed .Li JH , Li B , Jiang HR , Zhong MZ : [ Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].", "label": "", "metadata": {}, "score": "68.24039"}
{"text": "Yoshida Y , Sugawara N , Minami T , Iwata N , Ikeda K , Endoh T and Sasano H : A case of pancreatic neuroendocrine tumor with excessively - advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long - acting somatostatin analogue octreotide .", "label": "", "metadata": {}, "score": "68.24774"}
{"text": "[ 7 ] [ Level of evidence : 3iiiDiv ] Gemcitabine has shown activity in phase II trials of patients with metastatic bladder cancer .Although this study was not designed to show the equivalence of the two regimens , the similar efficacy and reduced toxic effects of GC make it a reasonable alternative in patients who may not tolerate the M - VAC regimen .", "label": "", "metadata": {}, "score": "68.27174"}
{"text": "Socinski MA , Morris DE , Masters GA , Lilenbaum R ( 2003 )Chemotherapeutic management of stage IV non - small cell lung cancer .", "label": "", "metadata": {}, "score": "68.51189"}
{"text": "Prospective validation of the International Union Against Cancer TNM classification .Cancer 70(5):1102 - 1110 PubMed CrossRef .Mountain CF ( 1997 ) Revisions in the international system for staging lung cancer .", "label": "", "metadata": {}, "score": "68.586205"}
{"text": "155 - 161 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Stokes , N. J. Nolan , E. B. Stelow et al . , \" Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer , \" Annals of Surgical Oncology , vol .", "label": "", "metadata": {}, "score": "68.692635"}
{"text": "The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer : a prospective comparative trial .J Urol 145 ( 3 ) : 459 - 64 ; discussion 464 - 7 , 1991 .", "label": "", "metadata": {}, "score": "68.81906"}
{"text": "Belani CP , Fossella F ( 2005 ) Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first - line treatment of advanced nonsmall cell lung carcinoma ( TAX 326 ) .", "label": "", "metadata": {}, "score": "68.84055"}
{"text": "After surgery for advanced pancreatic cancer , patients typically receive gemcitabine , which has been shown to lengthen survival by several months compared with surgery alone .", "label": "", "metadata": {}, "score": "68.846985"}
{"text": "This study is being supported by a grant from the Nanjing LUYE Pharmaceutical Co. , Ltd. .Competing interests .All the authors declare no conflict of interest .", "label": "", "metadata": {}, "score": "68.86102"}
{"text": "16 ] on 18 patients with borderline resectable and unresectable pancreatic cancer showed a 28 % rate of R0 resection after chemotherapy .Among the 11 patients who remained unresectable after FOLFIRINOX , 3 went on to have R0 resections after combined chemoradiotherapy , for an overall R0 resection rate of 44 % .", "label": "", "metadata": {}, "score": "68.87721"}
{"text": "Ardizzoni A , Boni L , Tiseo M et al ( 2007 ) Cisplatin- versus carboplatin - based chemotherapy in first - line treatment of advanced non - small - cell lung cancer : an individual patient data meta - analysis .", "label": "", "metadata": {}, "score": "68.9066"}
{"text": "Quality of life data have not yet been published regarding this regimen , and this study does not address the efficacy of nab - paclitaxel / gemcitabine versus FOLFIRINOX .", "label": "", "metadata": {}, "score": "68.93498"}
{"text": "Jemal A , Bray F , Center MM , Ferlay J , Ward E , Forman D : Global cancer statistics .CA Cancer J Clin 2011 , 61 : 69 - 90 .", "label": "", "metadata": {}, "score": "68.95846"}
{"text": "CA 27469 to the Gyneco- logic Oncology Group Administrative Office and CA 37517 to the Gyneco- logic Oncology Group Statistical and Data Center .ICON5 was funded by the MRC and has been supported by the NCRN through Grant No .", "label": "", "metadata": {}, "score": "69.01412"}
{"text": "Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy .Drug : cisplatin Drug : gemcitabine hydrochloride Drug : paclitaxel Procedure : conventional surgery Radiation : radiation therapy .", "label": "", "metadata": {}, "score": "69.06322"}
{"text": "Konety BR , Joslyn SA , O'Donnell MA : Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer : analysis of data from the Surveillance , Epidemiology and End Results Program data base .", "label": "", "metadata": {}, "score": "69.1122"}
{"text": "Treatment Options Under Clinical Evaluation for Stage III Pancreatic Cancer .Treatment options under clinical evaluation include the following : .For patients with unresectable tumors , clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy ( RTOG - PA-0020 is one example ) .", "label": "", "metadata": {}, "score": "69.157394"}
{"text": "Surgery will be suggested if the TNM stage of the tumor reduces sufficiently for the lesion to become resectable ; in such cases , the relevant chemotherapy regimen will continue after surgery .", "label": "", "metadata": {}, "score": "69.190475"}
{"text": "Endocr Relat Cancer .2012 Nov 6;19(6):751 - 7 .Welin S , Sorbye H , Sebjornsen S , Knappskog S , Busch C , Oberg K. Clinical effect of temozolomide - based chemotherapy in poorly differentiated endocrine carcinoma after progression on first - line chemotherapy .", "label": "", "metadata": {}, "score": "69.24402"}
{"text": "Poorly differentiated pNET is a rare neoplasm , associated with poor prognosis .The review of literature revealed only one similar report in which the patient received gemcitabine as third - line therapy [ 10].", "label": "", "metadata": {}, "score": "69.26798"}
{"text": "The optimal neoadjuvant therapy in patients with BRPC and LAPC remains a matter of debate due to the lack of randomized studies .In both categories local tumour reduction and systemic control represent primary goals of treatment and then common strategies may be applied in both entities .", "label": "", "metadata": {}, "score": "69.359726"}
{"text": "Although the use of preoperative treatment , such as neoadjuvant chemotherapy or chemoradiotherapy , may represent an effective strategy for localized PDAC , limited evidences are currently available on this approach .", "label": "", "metadata": {}, "score": "69.39121"}
{"text": "Urology 53 ( 2 ) : 243 - 50 , 1999 .Sweeney CJ , Roth BJ , Kabbinavar FF , et al .: Phase II study of pemetrexed for second - line treatment of transitional cell cancer of the urothelium .", "label": "", "metadata": {}, "score": "69.40854"}
{"text": "All authors have made a substantial contribution to this manuscript and study design in regards to conception , design , and drafting .GL and WYL are the treating physicians for the participants and are also involved in patient recruitment and treatment ; ZBJ is involved in data collection and patient follow - up , and XRF is providing statistical assistance .", "label": "", "metadata": {}, "score": "69.480034"}
{"text": "This analysis suggests that neoadjuvant treatment may be able to induce conversion to resectability in about one - third of LAPC patients and , importantly , tumour resection is associated with significantly prolonged overall survival , comparable to what was observed in primarily resectable pancreatic cancer patients .", "label": "", "metadata": {}, "score": "69.49437"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. S. Gunturu , X. Yao , X. Cong et al . , \" FOLFIRINOX for locally advanced and metastatic pancreatic cancer : single institution retrospective review of efficacy and toxicity , \" Medical Oncology , vol .", "label": "", "metadata": {}, "score": "69.53309"}
{"text": "The objective response rate ( ORR ) , changes in regional lymphatic metastasis ( including number and size ) and TNM ( tumor , node , metastasis ) staging will be the primary outcome measures .", "label": "", "metadata": {}, "score": "69.54782"}
{"text": "Final results of the CONKO 003 study .[Abstract ] J Clin Oncol 26 ( Suppl 15 ) : A-4508 , 2008 .Pelzer U , Schwaner I , Stieler J , et al .", "label": "", "metadata": {}, "score": "69.55246"}
{"text": "Final results of the CONKO 003 study .[Abstract ] J Clin Oncol 26 ( Suppl 15 ) : A-4508 , 2008 .Pelzer U , Schwaner I , Stieler J , et al .", "label": "", "metadata": {}, "score": "69.55246"}
{"text": "Nab - paclitaxel / gemcitabine was more toxic than gemcitabine .Febrile neutropenia occurred in 3 % of the nab - paclitaxel / gemcitabine group versus 1 % in the gemcitabine group .", "label": "", "metadata": {}, "score": "69.59583"}
{"text": "Yamamoto M , Miyagawa K , Hiura M , Taguchi M , Kihara Y , Abe S , Shimajiri S and Harada M : Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1 .", "label": "", "metadata": {}, "score": "69.7504"}
{"text": "Int J Radiat Oncol Biol Phys 50 ( 3 ) : 651 - 8 , 2001 .Stage IV Pancreatic Cancer Treatment .Treatment Options for Stage IV Pancreatic Cancer .", "label": "", "metadata": {}, "score": "69.76619"}
{"text": "Current Clinical Trials .Check for U.S. clinical trials from NCI 's list of cancer clinical trials that are now accepting patients with stage IV pancreatic cancer .", "label": "", "metadata": {}, "score": "69.77315"}
{"text": "It took longer for the disease to progress again in the maintenance group than in the observation group ( 11.5 v 15.4 months ) .The median overall survival in the maintenance group was 21.7 months compared with 17.9 months in the observation group .", "label": "", "metadata": {}, "score": "69.80026"}
{"text": "Ann Oncol 2010 , 21 : 2227 - 2232 .PubMed View Article .Zhang Q , Huang XE , Gao LL : A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors .", "label": "", "metadata": {}, "score": "69.83008"}
{"text": "A two - tailed test will be used for all statistics .Discussion .Lung cancer is the most common cancer worldwide , with NSCLC accounting for 85 % of cases [ 20 ] .", "label": "", "metadata": {}, "score": "69.83602"}
{"text": "Delbaldo C , Michiels S , Syz N , Soria JC , Le Chevalier T , Pignon JP ( 2004 ) Benefits of adding a drug to a single - agent or a 2-agent chemotherapy regimen in advanced non - small - cell lung cancer : a meta - analysis .", "label": "", "metadata": {}, "score": "69.87377"}
{"text": "BMJ 311(7010):899 - 909 .Brown J , Thorpe H , Napp V et al ( 2005 ) Assessment of quality of life in the supportive care setting of the big lung trial in non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "69.89457"}
{"text": "12 , pp .1200 - 1210 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. H. Klinkenbijl , J. Jeekel , T. Sahmoud et al . , \" Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group , \" Annals of Surgery , vol .", "label": "", "metadata": {}, "score": "69.954475"}
{"text": "15 , pp .2526 - 2531 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. B. Evans , G. R. Varadhachary , C. H. Crane , et al . , \" Preoperative gemcitabine - based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "69.96538"}
{"text": "Chemotherapy agents that have shown activity in metastatic bladder cancer include paclitaxel , docetaxel , ifosfamide , gallium nitrate , gemcitabine , and pemetrexed .[ 34 , 35 , 36 ] [ Level of evidence : 3iiiDiv ] .", "label": "", "metadata": {}, "score": "69.973816"}
{"text": "Table 2 : FOLFIRINOX regimen in patients with borderline resectable or locally advanced unresectable pancreatic cancer .A retrospective analysis conducted by Hosein et al .", "label": "", "metadata": {}, "score": "70.04545"}
{"text": "Ann Oncol 15:100 - 103 , 2004 2 .Gordon AN , Tonda M , Sun S , et al : Long - term survival advantage for women treated with pegy- lated liposomal doxorubicin compared with topote- can in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer .", "label": "", "metadata": {}, "score": "70.04559"}
{"text": "References : .Vieweg J , Gschwend JE , Herr HW , et al .: The impact of primary stage on survival in patients with lymph node positive bladder cancer .", "label": "", "metadata": {}, "score": "70.07211"}
{"text": "5 , pp .833 - 846 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Massucco , L. Capussotti , A. Magnino et al . , \" Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma : analysis of perioperative outcome and survival , \" Annals of Surgical Oncology , vol .", "label": "", "metadata": {}, "score": "70.09638"}
{"text": ": Adjuvant chemotherapy of bladder cancer : a preliminary report .J Urol 139 ( 6 ) : 1207 - 11 , 1988 .Skinner DG , Daniels JR , Russell CA , et al .", "label": "", "metadata": {}, "score": "70.09966"}
{"text": "Large phase III study establishes a new standard treatment option for patients with metastatic pancreatic cancer .In the United States , pancreatic cancer is the fourth - leading cause of cancer - related death .", "label": "", "metadata": {}, "score": "70.13097"}
{"text": "Siegel R , Naishadham D , Jemal A : Cancer statistics , 2013 .CA Cancer J Clin 63 ( 1 ) : 11 - 30 , 2013 .", "label": "", "metadata": {}, "score": "70.13591"}
{"text": "Check for U.S. clinical trials from NCI 's list of cancer clinical trials that are now accepting patients with stage IV bladder cancer .The list of clinical trials can be further narrowed by location , drug , intervention , and other criteria .", "label": "", "metadata": {}, "score": "70.142044"}
{"text": "PubMed View Article .Ma Q , Liu D , Guo Y , Shi B , Song Z , Tian Y : Surgical therapeutic strategy for non - small cell lung cancer with mediastinal lymph node metastasis ( N2 ) .", "label": "", "metadata": {}, "score": "70.16145"}
{"text": "GOG 87-L -Phase II Evaluation of Docetaxel and Gemcitabine Plus G - CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus .", "label": "", "metadata": {}, "score": "70.164604"}
{"text": "Gemcitabine is an effective active agent against untreated and recurrent small - cell carcinoma of lung [ 14 , 15].The response rate to gemcitabine was reported to be 27 % in patients with previously untreated small - cell carcinoma of lung [ 14].", "label": "", "metadata": {}, "score": "70.17468"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. L. Lee , S. C. Kim , J. H. Kim et al . , \" Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline - resectable or unresectable locally advanced pancreatic adenocarcinoma , \" Surgery , vol .", "label": "", "metadata": {}, "score": "70.2586"}
{"text": "Clinical trials are appropriate alternatives for treatment of patients with any stage of disease and should be considered before palliative approaches are selected .Information about ongoing clinical trials for pancreatic cancer is available from the NCI website .", "label": "", "metadata": {}, "score": "70.31105"}
{"text": "Kachnic LA , Kaufman DS , Heney NM , et al .: Bladder preservation by combined modality therapy for invasive bladder cancer .J Clin Oncol 15 ( 3 ) : 1022 - 9 , 1997 .", "label": "", "metadata": {}, "score": "70.313675"}
{"text": "Quality of life data have not yet been published regarding this regimen , and this study does not address the efficacy of nab - paclitaxel - gemcitabine versus FOLFIRINOX .", "label": "", "metadata": {}, "score": "70.32919"}
{"text": "The R0 resection rate was quite high ( 87 % ) while the perioperative morbidity was 40 % , in line with data from surgical series and then with no apparent increase in complication rates compared to surgery alone [ 15 ] .", "label": "", "metadata": {}, "score": "70.350136"}
{"text": "Lancet 358 ( 9293 ) : 1576 - 85 , 2001 .Neoptolemos JP , Stocken DD , Friess H , et al .: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer .", "label": "", "metadata": {}, "score": "70.35308"}
{"text": "The primary factors that influence prognosis are : .Whether the tumor is localized and can be completely resected .Whether the tumor has spread to lymph nodes or elsewhere .", "label": "", "metadata": {}, "score": "70.4977"}
{"text": "Treatment Options Under Clinical Evaluation for Stage IV Pancreatic Cancer .Treatment options under clinical evaluation include the following : .Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy .", "label": "", "metadata": {}, "score": "70.58238"}
{"text": "18 , pp .1691 - 1703 , 2013 .View at Publisher \u00b7 View at Google Scholar RATIONALE : Radiation therapy uses x - rays to damage tumor cells .", "label": "", "metadata": {}, "score": "70.627716"}
{"text": "Ann Oncol 7 ( 4 ) : 347 - 53 , 1996 .MacDonald JS , Widerlite L , Schein PS : Biology , diagnosis , and chemotherapeutic management of pancreatic malignancy .", "label": "", "metadata": {}, "score": "70.653336"}
{"text": "Full - text \u00b7 Article \u00b7 Nov 2014 \u00b7 Biochemical and Biophysical Research Communications .[ Show abstract ] [ Hide abstract ] ABSTRACT : The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays ( CSRAs ) , specifically as applied to epithelial ovarian cancer .", "label": "", "metadata": {}, "score": "70.65384"}
{"text": "The development of new interventions beyond surgery and conventional platinum - based chemother- apy is required to additionally improve outcomes for women with advanced EOC .", "label": "", "metadata": {}, "score": "70.67636"}
{"text": "Abstract ] Int J Radiat Oncol Biol Phys 69 ( 3 Suppl ) : A-14 , S8 , 2007 .Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier ( NCT Number ) : .", "label": "", "metadata": {}, "score": "70.74975"}
{"text": "PubMed View Article .Tsuchida Y , Therasse P : Response evaluation criteria in solid tumors ( RECIST ) : new guidelines .Med Pediatr Oncol 2001 , 37 : 1 - 3 .", "label": "", "metadata": {}, "score": "70.8035"}
{"text": "Approximately 20 % of patients present with pancreatic cancer amenable to local surgical resection , with operative mortality rates of approximately 1 % to 16 % .", "label": "", "metadata": {}, "score": "70.884"}
{"text": "Octreotide LAR did not extend overall survival in the high - hepatic load subgroup .The benefit of octreotide in patients with midgut neuroendocrine tumors has been debated for some time .", "label": "", "metadata": {}, "score": "70.99525"}
{"text": "Sohn TA , Lillemoe KD , Cameron JL , et al .: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s .J Am Coll Surg 188 ( 6 ) : 658 - 66 ; discussion 666 - 9 , 1999 .", "label": "", "metadata": {}, "score": "71.0264"}
{"text": "Sohn TA , Lillemoe KD , Cameron JL , et al .: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s .J Am Coll Surg 188 ( 6 ) : 658 - 66 ; discussion 666 - 9 , 1999 .", "label": "", "metadata": {}, "score": "71.0264"}
{"text": "To determine if incorporation of an additional cytotoxic agent improves overall survival ( OS ) and progression - free survival ( PFS ) for women with advanced - stage epithelial ovarian carcinoma ( EOC ) and primary peritoneal carcinoma who receive carboplatin and paclitaxel .", "label": "", "metadata": {}, "score": "71.04974"}
{"text": "Grilli R , Oxman AD , Julian JA ( 1993 ) Chemotherapy for advanced non - small - cell lung cancer : how much benefit is enough ?", "label": "", "metadata": {}, "score": "71.05792"}
{"text": ": Phase II study of gemcitabine in patients with advanced pancreatic cancer .Br J Cancer 73 ( 1 ) : 101 - 5 , 1996 .", "label": "", "metadata": {}, "score": "71.08991"}
{"text": "Chemotherapy occasionally produces objective antitumor response , but the low percentage of significant responses and lack of survival advantage warrant use of therapies under evaluation .", "label": "", "metadata": {}, "score": "71.16469"}
{"text": "Ongoing Trial in Neoadjuvant Setting for PDAC .Among the 1607 studies running in patients with pancreatic cancer , 91 studies are focused on neoadjuvant chemotherapy .", "label": "", "metadata": {}, "score": "71.205444"}
{"text": "Occasionally , patients have palliation of symptoms when treated with chemotherapy with well - tested older drugs , such as 5-FU .Gemcitabine has demonstrated activity in patients with pancreatic cancer and is a useful palliative agent .", "label": "", "metadata": {}, "score": "71.2104"}
{"text": "Eur J Cancer 47 ( 11 ) : 1676 - 81 , 2011 .Rougier P , Adenis A , Ducreux M , et al .", "label": "", "metadata": {}, "score": "71.22612"}
{"text": "In this chapter , we will present the key data that support the use of chemotherapy and biologic agents for the first - line treatment of advanced NSCLC .", "label": "", "metadata": {}, "score": "71.33429"}
{"text": "Treatment options under clinical evaluation include the following : .Gemcitabine and capecitabine ( ESPAC-4 ) .Gemcitabine and erlotinib ( CONKO-005 ) .Gemcitabine and erlotinib with or without 5-FU / capecitabine - based chemoradiation ( RTOG-0848 ) .", "label": "", "metadata": {}, "score": "71.34204"}
{"text": ": Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group .", "label": "", "metadata": {}, "score": "71.35455"}
{"text": ": Gemcitabine and carboplatin combination as first - line treatment in elderly patients and those unfit for cisplatin - based chemotherapy with advanced bladder carcinoma : Phase II study of the Hellenic Co - operative Oncology Group .", "label": "", "metadata": {}, "score": "71.36275"}
{"text": "2 Compared with patients in the observation group , patients in the maintenance treatment group experienced a substantially longer time to first progression ( 7.1 v 4.1 months ) .", "label": "", "metadata": {}, "score": "71.407974"}
{"text": "Cancer 74(7 Suppl):2101 - 2106 PubMed CrossRef .Lewis JH , Kilgore ML , Goldman DP et al ( 2003 ) Participation of patients 65 years of age or older in cancer clinical trials .", "label": "", "metadata": {}, "score": "71.42638"}
{"text": "The neuroendocrine tumors ( NET ) are classified by WHO ( Table 1 ) based on their differentiation in order to assess their biological behavior and their potential for a malignant phenotype [ 2].", "label": "", "metadata": {}, "score": "71.45442"}
{"text": "[ 9 ] .[ 6 ] .The trial reported no difference in OS between the two groups .F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive - Soci\u00e9t\u00e9 Fran\u00e7aise de Radioth\u00e9rapie Oncologie ( FFCD - SFRO ) trial : As it became clear that radiation therapy alone was an inadequate treatment , investigators evaluated combined modality approaches versus chemotherapy alone .", "label": "", "metadata": {}, "score": "71.47287"}
{"text": "CT scan after an additional three cycles ( 9 weeks ) showed stable disease but patient requested to stop therapy .He decided to go for holistic treatment .", "label": "", "metadata": {}, "score": "71.51132"}
{"text": "Logothetis CJ , Dexeus FH , Finn L , et al .: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors .", "label": "", "metadata": {}, "score": "71.513725"}
{"text": ": An investigational new drug treatment program for patients with gemcitabine : results for over 3000 patients with pancreatic carcinoma .Cancer 85 ( 6 ) : 1261 - 8 , 1999 .", "label": "", "metadata": {}, "score": "71.543076"}
{"text": "Smith D , Gallagher N : A phase II / III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer .Eur J Cancer 39 ( 10 ) : 1377 - 83 , 2003 .", "label": "", "metadata": {}, "score": "71.58453"}
{"text": "Objective .This clinical trial aims to determine whether first - line therapy using liposomal paclitaxel combined with cisplatin ( LP regimen ) is more effective and safer than gemcitabine combined with cisplatin ( GP regimen ) for patients with NSCLC with regional lymphatic metastasis .", "label": "", "metadata": {}, "score": "71.59853"}
{"text": "J Urol 149 ( 5 ) : 957 - 72 , 1993 .Grossman HB , Natale RB , Tangen CM , et al .: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer .", "label": "", "metadata": {}, "score": "71.70214"}
{"text": "Several studies are assessing the efficacy of gemcitabine alone or in combination with other drugs in this setting .Among them , a multicenter prospective randomized phase II / III study of neoadjuvant chemoradiation with gemcitabine is ongoing in patients with borderline resectable pancreatic cancer .", "label": "", "metadata": {}, "score": "71.72659"}
{"text": "Postoperative chemoradiation therapy : radical pancreatic resection followed by 5-fluorouracil ( 5-FU ) chemotherapy and radiation therapy .[ 3 , 4 , 5 , 6 , 7 ] .", "label": "", "metadata": {}, "score": "71.8092"}
{"text": "These results confirm a positive effect of neoadjuvant treatment in terms of resection rates and long - term survival in patients with BRPC .However , the high rates of disease relapse claim for more effective treatments .", "label": "", "metadata": {}, "score": "71.82514"}
{"text": "Cancer 80 ( 10 ) : 1966 - 72 , 1997 .Bellmunt J , de Wit R , Albanell J , et al .:", "label": "", "metadata": {}, "score": "71.97867"}
{"text": "Tumor markers .No tumor - specific markers exist for pancreatic cancer ; markers such as serum cancer antigen ( CA ) 19 - 9 have low specificity .", "label": "", "metadata": {}, "score": "72.00096"}
{"text": "Definitive results of the 2000 - 01 FFCD / SFRO study .Ann Oncol 19 ( 9 ) : 1592 - 9 , 2008 .Huguet F , Andr\u00e9 T , Hammel P , et al .", "label": "", "metadata": {}, "score": "72.00898"}
{"text": "Page 2 . ( GOG ) in the United States and by the Medical Research Council ( MRC ) in the United Kingdom ( MRC - UK ) , which represents the InternationalCollaborativeOvarianNeoplasm(ICON)group .", "label": "", "metadata": {}, "score": "72.129105"}
{"text": "Currently available data do not allow defining an optimal regimen in this setting .Combination chemotherapy appears to achieve higher response rates than single - agent chemotherapy , while there are no sufficient evidences to show that chemoradiotherapy is superior to chemotherapy alone .", "label": "", "metadata": {}, "score": "72.13452"}
{"text": "Pfister DG , Johnson DH , Azzoli CG et al ( 2004 ) American Society of Clinical Oncology treatment of unresectable non - small - cell lung cancer guideline : update 2003 .", "label": "", "metadata": {}, "score": "72.17262"}
{"text": "TRIBUTE : a phase III trial of erlotinib hydrochloride ( OSI-774 ) combined with carboplatin and paclitaxel chemotherapy in advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "72.190094"}
{"text": "Conventional imaging studies , such a computed tomography ( CT ) scan are usually sufficient for localization of the primary tumor and hepatic metastases .18 F - fluorodeoxyglucose positron emission tomography ( PET ) can provide additional information in some cases .", "label": "", "metadata": {}, "score": "72.19728"}
{"text": "Gemcitabine alone versus gemcitabine and erlotinib : The National Cancer Institute of Canada performed a phase III trial ( CAN - NCIC - PA3 [ NCT00026338 ] ) that compared gemcitabine alone versus the combination of gemcitabine and erlotinib ( 100 mg / day ) in patients with advanced or metastatic pancreatic carcinomas .", "label": "", "metadata": {}, "score": "72.25023"}
{"text": "O'Connell MJ : Current status of chemotherapy for advanced pancreatic and gastric cancer .J Clin Oncol 3 ( 7 ) : 1032 - 9 , 1985 .", "label": "", "metadata": {}, "score": "72.27367"}
{"text": "Median OS was 23.1 months in patients undergoing surgery [ 32 ] .An Italian study evaluated an upfront intensive chemotherapy combination followed by chemoradiotherapy in the treatment of LAPC .", "label": "", "metadata": {}, "score": "72.30199"}
{"text": "Evidence : ( chemotherapy ) : .Gemcitabine versus 5-FU : Gemcitabine has demonstrated activity in patients with pancreatic cancer and is a useful palliative agent .", "label": "", "metadata": {}, "score": "72.33438"}
{"text": "Poorly differentiated neuroendocrine carcinomas ( G3 ) .- Median survival duration - 5-year survival .34 months 38 % .14 months 21 % .", "label": "", "metadata": {}, "score": "72.43839"}
{"text": "In patients with borderline resectable or nonresectable pancreatic cancer , neoadjuvant therapy may achieve downsizing of the tumour , increasing the probability of R0 resections , or may convert the tumour to become resectable .", "label": "", "metadata": {}, "score": "72.52446"}
{"text": "PubMed .Prieto Garcia A , PinedadelaLosa F : Immunoglobulin E - mediated severe anaphylaxis to paclitaxel .J Investig Allergol Clin Immunol 2010 , 20 : 170 - 171 .", "label": "", "metadata": {}, "score": "72.60574"}
{"text": "Also the combination of gemcitabine and capecitabine has been assessed in this subset of patients .In a study by Lee et al ., forty - three patients ( 18 with BRPC and 25 with unresectable disease ) were treated with fixed - dose rate gemcitabine and capecitabine .", "label": "", "metadata": {}, "score": "72.61252"}
{"text": "In large series a 92 % rate of disease relapse has been reported after PDAC resection without postoperative treatment .In particular , local recurrence occurs in about 40 % of patients while distant metastases are observed as the only site of relapse in about 50 % of cases , with liver as the primary site of distant relapse ( 36 % ) [ 3 ] .", "label": "", "metadata": {}, "score": "72.64757"}
{"text": "Orlando , FL , USA .January 22 - 24 , 2010 .JOP .J Clin Oncol .Eriksson B , Oberg K and Skogseid B : Neuroendocrine pancreatic tumors .", "label": "", "metadata": {}, "score": "72.777916"}
{"text": "Adjuvant combined radiation and chemotherapy following curative resection .Arch Surg 120 ( 8) : 899 - 903 , 1985 .Klinkenbijl JH , Jeekel J , Sahmoud T , et al .", "label": "", "metadata": {}, "score": "72.77821"}
{"text": "Keywords .Non - small cell lung cancer Frontline First - line Chemotherapy Biologic agents .Other actions .Share .References .Bulzebruck H , Bopp R , Drings P et al ( 1992 )", "label": "", "metadata": {}, "score": "72.91157"}
{"text": "What was the outcome of the AE ?The severity of the AE will be graded using National Cancer Institute Common Toxicity Criteria ( NCICTC,3rd edition ) for drug - associated AEs .", "label": "", "metadata": {}, "score": "72.91556"}
{"text": "Inclusion criteria .Eastern Cooperative Oncology Group ( ECOG ) performance status of 0 to 2 .Pathological diagnosis of non - small cell lung cancer , TNM stage III to IV .", "label": "", "metadata": {}, "score": "72.99748"}
{"text": "The active component of S-1 , tegafur , is converted in the bloodstream to fluorouracil , which is FDA approved to treat pancreatic cancer .Previous studies have shown that S-1 is more toxic for patients of European descent , requiring use of lower doses .", "label": "", "metadata": {}, "score": "73.02258"}
{"text": "Patients with any stage of pancreatic cancer can appropriately be considered candidates for clinical trials because of the poor response to chemotherapy , radiation therapy , and surgery as conventionally used .", "label": "", "metadata": {}, "score": "73.04617"}
{"text": "Clinicopathologic analysis of 5-year survivors .Ann Surg 223 ( 3 ) : 273 - 9 , 1996 .Yeo CJ , Abrams RA , Grochow LB , et al .", "label": "", "metadata": {}, "score": "73.06731"}
{"text": "Statistical Design Stratified block random assignment was used to balance treatment as- signments within coordinating center , residual disease status , and intention Table 1 .", "label": "", "metadata": {}, "score": "73.08857"}
{"text": "Although there was some increase in size of liver metastases at that time , overall her CT scan showed stable disease .The patient requested that the therapy would be stopped because of malaise and fatigue .", "label": "", "metadata": {}, "score": "73.09442"}
{"text": "Median OS was 9.09 months for the sequence of gemcitabine ( GEM)-OFF and 7.90 months for GEM - BSC .The early closure of the study and the very small number of patients made the P values misleading .", "label": "", "metadata": {}, "score": "73.171135"}
{"text": "Median OS was 9.09 months for the sequence of gemcitabine ( GEM)-OFF and 7.90 months for GEM - BSC .The early closure of the study and the very small number of patients made the P values misleading .", "label": "", "metadata": {}, "score": "73.171135"}
{"text": "[ 10 ] .The highest cure rate occurs if the tumor is truly localized to the pancreas ; however , this stage of disease accounts for less than 20 % of cases .", "label": "", "metadata": {}, "score": "73.22985"}
{"text": "In addition to clinical outcomes , the study would also provide an international clinical re- search database , including outcomes in patients with uncommon histologiesandgeneticmutationsassociatedwithcancerrisk .", "label": "", "metadata": {}, "score": "73.2352"}
{"text": "After three cycles of gemcitabine , a CT scan showed stable disease .He continued gemcitabine for another three cycles ( 18 weeks ) when the restaging CT scan showed 18 % increase but stable disease .", "label": "", "metadata": {}, "score": "73.26541"}
{"text": "Cameron JL , Crist DW , Sitzmann JV , et al .: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer .Am J Surg 161 ( 1 ) : 120 - 4 ; discussion 124 - 5 , 1991 .", "label": "", "metadata": {}, "score": "73.3308"}
{"text": "Stage IV bladder cancer is defined by the following TNM classifications : .T4b , N0 , M0 .Currently , only a small fraction of patients with stage IV bladder carcinoma can be cured .", "label": "", "metadata": {}, "score": "73.36786"}
{"text": "Furthermore , neoadjuvant treatment allows evaluation of tumour response and increases patient 's compliance .However , most evidences in this setting come from retrospective analysis or small case series and in many studies chemotherapy or chemoradiation therapies used were suboptimal .", "label": "", "metadata": {}, "score": "73.435875"}
{"text": "Chemoradiotherapy did not increase perioperative morbidity and mortality .Median overall survival for the whole group was 15 months .In both groups , a disease - free survival beyond 24 months was observed in patients resected with negative margins .", "label": "", "metadata": {}, "score": "73.52933"}
{"text": "DISCUSSION .Gemcitabine is a deoxycytidine analog similar to the pyrimidine antimetabolite cytarabine , with activity against solid tumors .Gemcitabine is approved by the U.S. Food and Drug Administration ( FDA ) for the treatment of patients with pancreatic cancer , non - small - cell lung cancer and bladder cancer [ 8].", "label": "", "metadata": {}, "score": "73.579834"}
{"text": "Overall resection rate was 53.8 % including 45 % of patients with initially unresectable disease and R0 resection was achieved in 85.7 % of the resected patients .", "label": "", "metadata": {}, "score": "73.5945"}
{"text": "The role of postoperative therapy ( chemotherapy with or without chemoradiation therapy ) in the management of pancreatic cancer remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results .", "label": "", "metadata": {}, "score": "73.74413"}
{"text": "Kyrgiou M , Salanti G , Pavlidis N , et al : Survival benefits with diverse chemotherapy regimens for ovarian cancer : Meta - analysis of multiple treat- ments .", "label": "", "metadata": {}, "score": "73.96655"}
{"text": "Atolerabletripletregimenhasbeendescribedwithcisplatin , butthis wouldhavechangedtheoveralltrialdesign.9 PLDhasprolongedclearancebecauseofpolyethyleneglycolandliposo- mal encapsulation .In pilot studies , dosing every 3 weeks was associated with an unacceptable risk of mucosal , skin , and/or hematologic toxicity .", "label": "", "metadata": {}, "score": "74.02879"}
{"text": "Distant metastasis [ Time Frame : From start of protocol treatment to date of distant metastasis ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.04993"}
{"text": "PubMed View Article .Davidoff AJ , Tang M , Seal B , Edelman MJ : Chemotherapy and survival benefit in elderly patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "74.0547"}
{"text": "N Engl J Med 344 ( 22 ) : 1681 - 7 , 2001 .Passik SD , Breitbart WS : Depression in patients with pancreatic carcinoma .", "label": "", "metadata": {}, "score": "74.07059"}
{"text": ": Pancreaticoduodenectomy for pancreatic adenocarcinoma : postoperative adjuvant chemoradiation improves survival .A prospective , single - institution experience .Ann Surg 225 ( 5 ) : 621 - 33 ; discussion 633 - 6 , 1997 .", "label": "", "metadata": {}, "score": "74.09854"}
{"text": ": Pancreaticoduodenectomy for pancreatic adenocarcinoma : postoperative adjuvant chemoradiation improves survival .A prospective , single - institution experience .Ann Surg 225 ( 5 ) : 621 - 33 ; discussion 633 - 6 , 1997 .", "label": "", "metadata": {}, "score": "74.09854"}
{"text": "Each drug carries its specific side effects , but gemcitabine has the least gastrointestinal side effect and modest effect on bone marrow .In addition , gemcitabine is the most commonly used drug to treat pancreatic adenocarcinoma and gives an ease to the treating oncologists as well [ 19].", "label": "", "metadata": {}, "score": "74.099785"}
{"text": "Well differentiated .Low grade ( G1 )Intermediate grade ( G2 ) .Neuroendocrine tumor , grade 1 Neuroendocrine tumor , grade 2 .Poorly differentiated .", "label": "", "metadata": {}, "score": "74.1842"}
{"text": "Most oncologists have experience administrating gemcitabine ; its toxicity profile is quite favorable and both the dose and schedule can be modified if needed .Since the prognosis of this population is terribly poor , our case series and other reports provide a growing evidence supporting benefit of chemotherapy after first - line failure in selected patients with good performance status .", "label": "", "metadata": {}, "score": "74.2569"}
{"text": "Gemcitabine compared with observation alone yielded improved survival rates at 5 years of 20.7 % for the gemcitabine arm versus 10.4 % for the observation - alone arm and at 10 years the survival rates were 12.2 % for the gemcitabine arm versus 7.7 % for the observation - alone arm .", "label": "", "metadata": {}, "score": "74.29039"}
{"text": "After treatment , 39 % of patients underwent curative resection , with a 69 % of R0 resections .Median OS of patients who underwent tumor resection was 22 months compared with 12 months for those without resection ( . )", "label": "", "metadata": {}, "score": "74.37347"}
{"text": "AJCC Stage Groupings and TNM Definitions .The American Joint Committee on Cancer ( AJCC ) has designated staging by TNM classification .[ 1 ] .", "label": "", "metadata": {}, "score": "74.427666"}
{"text": "These data will be held by both our department and the sponsor , and can not be modified .All participants will be enrolled in the final analysis regardless of whether they withdraw at any point .", "label": "", "metadata": {}, "score": "74.44008"}
{"text": "J Gastrointest Surg 4 ( 6 ) : 567 - 79 , 2000 Nov - Dec .Choti MA : Adjuvant therapy for pancreatic cancer -- the debate continues .", "label": "", "metadata": {}, "score": "74.44685"}
{"text": "Evaluationoftoxic- ities , complications , doseintensity , andcumulativedosedeliverywouldalsobe describedforeachregimen .Patient Selection Eligible patients submitted tissue to confirm histologic diagnosis ( EOC or primary peritoneal carcinoma [ PPC ] ) and International Federation of Gynecology and Obstetrics stage ( III or IV ) , with either optimal ( ? 1 cm ) or suboptimal residual disease .", "label": "", "metadata": {}, "score": "74.48933"}
{"text": "J Clin Oncol 26 ( Abstract no . 3 ) .Havlik RJ , Yancik R , Long S , Ries L , Edwards B ( 1994 )", "label": "", "metadata": {}, "score": "74.50716"}
{"text": "There was no significant increase in pulmonary toxicity associated withgemcitabine .The primary analysis of OS and an updated analysis of PFS are reported here .", "label": "", "metadata": {}, "score": "74.55463"}
{"text": "ULN , andbaselinesensoryormotorneuropathy grade 1 or lower according to National Cancer Institute Common Toxicity Criteriaversion2 .Patients who had tumors of low malignant potential , with carcinosar- coma , or with nonepithelial tumors were not eligible .", "label": "", "metadata": {}, "score": "74.58565"}
{"text": "In this study , we identified that mitochondrial division inhibitor-1 ( mdivi-1 ) is able to enhance the sensitivity of human ovarian cancer cells to death receptor ligands including TRAIL , FAS ligands , and TNF - \u03b1 .", "label": "", "metadata": {}, "score": "74.647385"}
{"text": "Jemal A , Siegel R , Xu J , Ward E : Cancer statistics , 2010 .CA Cancer J Clin 2010 , 60 : 277 - 300 .", "label": "", "metadata": {}, "score": "74.699615"}
{"text": "N\u00f6thlings U , Wilkens LR , Murphy SP , et al .:Meat and fat intake as risk factors for pancreatic cancer : the multiethnic cohort study .", "label": "", "metadata": {}, "score": "74.74177"}
{"text": "A prospective , single - institution experience .Ann Surg 225 ( 5 ) : 621 - 33 ; discussion 633 - 6 , 1997 .", "label": "", "metadata": {}, "score": "74.77205"}
{"text": "Stewart DJ ( 2008 )Gefitinib maintenance in stage III non - small - cell lung cancer .J Clin Oncol 26(29):4849 - 4850 ; author reply 50 - 51 PubMed CrossRef .", "label": "", "metadata": {}, "score": "74.804886"}
{"text": "Table 2 .The table shows the median survival and 5-year survival rates reported for all NETs according to disease grade and stage . 111 months 68 % .", "label": "", "metadata": {}, "score": "74.94614"}
{"text": "Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer .Gastrointestinal Tumor Study Group .Cancer 59 ( 12 ) : 2006 - 10 , 1987 .", "label": "", "metadata": {}, "score": "74.96994"}
{"text": "Several trials are in course to evaluate the use of capecitabine as neoadjuvant therapy for pancreatic cancer patients .Among them , a phase II trial has been opened to evaluate the efficacy and safety of the combination of capecitabine , oxaliplatin , and irinotecan ( CAPOXIRI ) in patients with resectable , borderline resectable , and locally advanced PDAC ( NCT01760252 ) .", "label": "", "metadata": {}, "score": "75.15193"}
{"text": "Abraxane represents one of the most promising agents for patients with pancreatic cancer .With regard to its use in the neoadjuvant setting , the NEONAX randomized phase II trial is in course to compare neoadjuvant plus adjuvant or only adjuvant nab - paclitaxel plus gemcitabine for resectable pancreatic cancer ( NCT02047513 ) .", "label": "", "metadata": {}, "score": "75.18147"}
{"text": "14 ] .( Refer to the Palliative Interventions section of the PDQ summary on Pain for more information . )References : .American Cancer Society : Cancer Facts and Figures 2015 .", "label": "", "metadata": {}, "score": "75.19795"}
{"text": "Site : Vulva .GOG 173 -Intraoperative Lymphatic Mapping and Sentinel Node Identification in Patients with Squamous Cell Carcinoma of the Vulva .GOG 205 -Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally Advanced Squamous Cell carcinoma of the Vulva .", "label": "", "metadata": {}, "score": "75.367035"}
{"text": "Cancer J 7 ( 4 ) : 312 - 23 , 2001 Jul - Aug .Balcom JH 4th , Rattner DW , Warshaw AL , et al .", "label": "", "metadata": {}, "score": "75.41074"}
{"text": "Lung Cancer 2007 , 57 : 168 - 174 .PubMed View Article .Sandler AB , Nemunaitis J , Denham C , von Pawel J , Cormier Y , Gatzemeier U , Mattson K , Manegold C , Palmer MC , Gregor A , et al .", "label": "", "metadata": {}, "score": "75.42091"}
{"text": "Chest 106(3):861 - 865 PubMed CrossRef .Souquet PJ , Chauvin F , Boissel JP et al ( 1993 )Polychemotherapy in advanced non small cell lung cancer : a meta - analysis .", "label": "", "metadata": {}, "score": "75.512634"}
{"text": "Grades 4 and 5 toxicity were greater in the chemoradiation therapy arm than in the chemotherapy arm ( 41 % vs. 9 % ) .Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie ( GERCOR ) : Given the increased toxicity of chemoradiation therapy and the early development of metastatic disease in a large percentage of patients with stage III pancreatic cancer , investigators are pursuing a strategy of selecting patients with localized disease for chemoradiation therapy .", "label": "", "metadata": {}, "score": "75.7184"}
{"text": "This approach has yet to be validated in a prospective phase III trial .Chemotherapy .Chemotherapy is the primary treatment modality for patients with locally advanced pancreatic cancers .", "label": "", "metadata": {}, "score": "75.74101"}
{"text": "Around 80 to 85 % of lung cancers are non - small cell lung cancer ( NSCLC ) , adequate therapeutic planning is largely dependent upon early diagnosis , and surgery is still the preferred treatment for early - stage tumors [ 2 ] .", "label": "", "metadata": {}, "score": "75.87497"}
{"text": "Other potential advantages include better patients ' tolerance to chemotherapy , a reduced risk of peritoneal tumour implantation during surgery , and the chance of an in vivo assessment of tumour chemosensitivity .", "label": "", "metadata": {}, "score": "75.91469"}
{"text": "LBA7514 ) .Ann Oncol 19(suppl 8):viii1 .Ciardiello F , Tortora G ( 2008 ) EGFR antagonists in cancer treatment .N Engl J Med 358(11):1160 - 1174 PubMed CrossRef .", "label": "", "metadata": {}, "score": "75.95873"}
{"text": "Chemotherapy with gemcitabine is a standard treatment for advanced pancreatic cancer .Adding other drugs to gemcitabine , such as erlotinib or capecitabine , has been shown to help some patients live longer .", "label": "", "metadata": {}, "score": "76.03238"}
{"text": "Moreover , two phase II studies are assessing the efficacy and safety of pre- and postsurgery FOLFIRINOX in patients with localized pancreatic cancer ( NCT01660711 , NCT02047474 ) .", "label": "", "metadata": {}, "score": "76.1334"}
{"text": "However , unlike so many others , we have yet to identify key drivers for our most common and most fatal cancers .Our future success lies in prospective tumor analysis and treatment assignments , replacing a one size fits all treatment pathway .", "label": "", "metadata": {}, "score": "76.1553"}
{"text": "Data collection and statistical analysis .Codes will be used to guarantee the privacy of the participants .The CRF will be used to record data for all participants .", "label": "", "metadata": {}, "score": "76.178604"}
{"text": "PubMed View Article .Moher D , Hopewell S , Schulz KF , Montori V , Gotzsche PC , Devereaux PJ , Elbourne D , Egger M , Altman DG : CONSORT 2010 explanation and elaboration : updated guidelines for reporting parallel group randomised trials .", "label": "", "metadata": {}, "score": "76.28041"}
{"text": "Vaughn DJ : Chemotherapeutic options for cisplatin - ineligible patients with advanced carcinoma of the urothelium .Cancer Treat Rev 34 ( 4 ) : 328 - 38 , 2008 .", "label": "", "metadata": {}, "score": "76.36942"}
{"text": "Context Poorly differentiated neuroendocrine carcinoma of the pancreas is a rare and aggressive tumor .The combination of etoposide and cisplatin is considered as the first - line treatment , but no recommendations exist for further treatment after progression .", "label": "", "metadata": {}, "score": "76.581894"}
{"text": "Tersmette AC , Petersen GM , Offerhaus GJ , et al .: Increased risk of incident pancreatic cancer among first - degree relatives of patients with familial pancreatic cancer .", "label": "", "metadata": {}, "score": "76.714264"}
{"text": "Evidence ( postoperative chemoradiation therapy ) : .Several phase III trials examined the potential overall survival ( OS ) benefit of postoperative adjuvant 5-FU - based chemoradiation therapy : .", "label": "", "metadata": {}, "score": "76.765366"}
{"text": "Treatment Option Overview for Pancreatic Cancer .Surgical resection remains the primary modality when feasible ; on occasion , resection can lead to long - term survival and provides effective palliation .", "label": "", "metadata": {}, "score": "76.82907"}
{"text": "Recent CSRA research and clinical studies are outlined in this review .Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs .Specifically , analytical and clinical validations , as well as clinical utility and economic benefit , of the most common clinically used CSRA in the United States support its use to aid in making effective , individualized clinical treatment selections for patients with ovarian cancer .", "label": "", "metadata": {}, "score": "76.97633"}
{"text": "Ann Surg 219 ( 1 ) : 18 - 24 , 1994 .Sohn TA , Lillemoe KD , Cameron JL , et al .: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s .", "label": "", "metadata": {}, "score": "76.99773"}
{"text": "The NCI has booklets and other materials for patients , health professionals , and the public .These publications discuss types of cancer , methods of cancer treatment , coping with cancer , and clinical trials .", "label": "", "metadata": {}, "score": "77.07004"}
{"text": "Int J Radiat Oncol Biol Phys 62 ( 5 ) : 1345 - 50 , 2005 .Chauffert B , Mornex F , Bonnetain F , et al .", "label": "", "metadata": {}, "score": "77.09191"}
{"text": "There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first - line and relapsed ( platinum - sensitive and resistant ) ovarian cancer .", "label": "", "metadata": {}, "score": "77.109146"}
{"text": "Marino P , Pampallona S , Preatoni A , Cantoni A , Invernizzi F ( 1994 ) Chemotherapy vs supportive care in advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "77.12281"}
{"text": "It does not provide formal guidelines or recommendations for making health care decisions .Reviewers and Updates .This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board , which is editorially independent of the National Cancer Institute ( NCI ) .", "label": "", "metadata": {}, "score": "77.187546"}
{"text": "Therefore , therapeutic strategies focusing on the issue of regional lymphatic metastasis are of great importance not only for the control of distant lung - cancer metastases , but also for reducing the TNM ( tumor , node , metastasis ) stage and thus regaining the opportunity for surgery .", "label": "", "metadata": {}, "score": "77.326515"}
{"text": "Patient demographic characteristics , prognostic factors ( including stage , histology , and measurable disease ) , and stratification parameters ( including maximal residual disease and intent to perform interval cytoreductive surgery ) .", "label": "", "metadata": {}, "score": "77.34677"}
{"text": "2011 Oct 15;117(20):4617 - 22 .Reports .Clinical Cancer Advances 2013 : Gastrointestinal Cancers .Specialty Editor : John Marshall , MD , Lombardi Cancer Center .", "label": "", "metadata": {}, "score": "77.42999"}
{"text": "Cancer 98(4):779 - 788 PubMed CrossRef .Gridelli C , Perrone F , Gallo C et al ( 2003 ) Chemotherapy for elderly patients with advanced non - small - cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study ( MILES ) phase III randomized trial .", "label": "", "metadata": {}, "score": "77.52774"}
{"text": "N Engl J Med 364 ( 19 ) : 1817 - 25 , 2011 .Pelzer U , Kubica K , Stieler J , et al .", "label": "", "metadata": {}, "score": "77.61942"}
{"text": "N Engl J Med 364 ( 19 ) : 1817 - 25 , 2011 .Pelzer U , Kubica K , Stieler J , et al .", "label": "", "metadata": {}, "score": "77.61942"}
{"text": "Tumors should be evaluated on the basis of the tumor - associated symptoms , physical examination of the superficial lesions , and results of imaging studies .", "label": "", "metadata": {}, "score": "77.673965"}
{"text": "Abstract ] J Clin Oncol 23 ( Suppl 16 ) : A-4506 , 379s , 2005 .Shipley WU , Bae K , Efstathiou JA , et al .", "label": "", "metadata": {}, "score": "77.8642"}
{"text": "This section describes the latest changes made to this summary as of the date above .Editorial changes were made to this summary .This summary is written and maintained by the PDQ Adult Treatment Editorial Board , which is editorially independent of NCI .", "label": "", "metadata": {}, "score": "77.89674"}
{"text": "PubMed View Article .Straubinger RM , Arnold RD , Zhou R , Mazurchuk R , Slack JE : Antivascular and antitumor activities of liposome - associated drugs .", "label": "", "metadata": {}, "score": "77.89877"}
{"text": "[ Time Frame : From start to end of all protocol therapy ] [ Designated as safety issue : No ] .Complete response after TCI induction [ Time Frame : From start to end of all protocol therapy ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "77.981285"}
{"text": "In this review , the authors examined available data on neoadjuvant treatment in patients with resectable pancreatic cancer as well as in patients with borderline resectable or locally advanced PDAC and the future directions in this peculiar setting .", "label": "", "metadata": {}, "score": "78.00183"}
{"text": "Semin Oncol 17 ( 5 ) : 555 - 65 , 1990 .Raghavan D , Huben R : Management of bladder cancer .Curr Probl Cancer 19 ( 1 ) : 1 - 64 , 1995 Jan - Feb .", "label": "", "metadata": {}, "score": "78.11374"}
{"text": "The use of imaging technology may aid in the diagnosis of pancreatic cancer and in the identification of patients with disease that is not amenable to resection .", "label": "", "metadata": {}, "score": "78.17164"}
{"text": ": Lack of efficacy of high - dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma .J Clin Oncol 9 ( 9 ) : 1682 - 6 , 1991 .", "label": "", "metadata": {}, "score": "78.21011"}
{"text": "Neoadjuvant Therapy in Borderline Resectable and in Locally Advanced PDAC .As previously stated , only 10 - 20 % of PDAC patients present with primarily resectable disease while locally advanced , nonmetastatic pancreatic cancer is seen in about 30 % of patients [ 1 ] and median OS in this subgroup of patients is in the order of 9 - 13 months .", "label": "", "metadata": {}, "score": "78.228226"}
{"text": "8011 ) .Ceppi P , Volante M , Saviozzi S et al ( 2006 ) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase .", "label": "", "metadata": {}, "score": "78.36283"}
{"text": "Hansen SW : Gemcitabine , platinum , and pac- litaxel regimens in patients with advanced ovarian carcinoma .Semin Oncol 29:17 - 19 , 2002 ( suppl 1 ) 26 .", "label": "", "metadata": {}, "score": "78.41962"}
{"text": "ECOG :The results of the FFCD - SFRO study stand in contrast to the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine .", "label": "", "metadata": {}, "score": "78.43278"}
{"text": "For information on eligibility criteria for the GOG studies listed below , contact Ann Gelder at 717 - 531 - 6218 or email agelder@psu.edu .Study Protocol .", "label": "", "metadata": {}, "score": "78.50659"}
{"text": "[Abstract ] J Clin Oncol 24 ( Suppl 18 ) : A-4008 , 180s , 2006 .Loehrer PJ Sr , Feng Y , Cardenes H , et al .", "label": "", "metadata": {}, "score": "78.50966"}
{"text": "Available online .Last accessed July 1 , 2015 .Silverman DT , Schiffman M , Everhart J , et al .: Diabetes mellitus , other medical conditions and familial history of cancer as risk factors for pancreatic cancer .", "label": "", "metadata": {}, "score": "78.60128"}
{"text": "Sohn TA , Yeo CJ , Cameron JL , et al .: Intraductal papillary mucinous neoplasms of the pancreas : an increasingly recognized clinicopathologic entity .", "label": "", "metadata": {}, "score": "78.60878"}
{"text": "Riker A , Libutti SK , Bartlett DL : Advances in the early detection , diagnosis , and staging of pancreatic cancer .Surg Oncol 6 ( 3 ) : 157 - 69 , 1997 .", "label": "", "metadata": {}, "score": "78.62356"}
{"text": ": Carcinoma of the pancreatic head and periampullary region .Tumor staging with laparoscopy and laparoscopic ultrasonography .Ann Surg 221 ( 2 ) : 156 - 64 , 1995 .", "label": "", "metadata": {}, "score": "78.702545"}
{"text": "The median OS of all 90 patients from the date of diagnosis was 17.4 months ( 95 % CI , 14.5 to 20.3 months ) while patients who completed chemoradiation and underwent surgery had a median OS of 31 months [ 13 ] .", "label": "", "metadata": {}, "score": "78.749565"}
{"text": "Palliative surgical biliary bypass , percutaneous radiologic biliary stent placement , or endoscopically placed biliary stents .[ 12 , 13 , 14 ] .Chemotherapy .", "label": "", "metadata": {}, "score": "78.751175"}
{"text": "Severe AEs will be reported to the local authorities within 24 hours , in accordance with the relevant procedures .Sample size .The patient sample size is based on our preliminary study , in which the ORRs of the LP and GP groups were found to be about 65 % and 35 % , respectively .", "label": "", "metadata": {}, "score": "79.19438"}
{"text": "Each of these agents has a unique molecular target , mechanism of action , andpatternofresistance , whichlendscredencetothedevelopment ofmultiagentcombinations .Inaddition , eachagenthasthepoten- tialtoaccentuatetheplatinumresponsethroughincreasedforma- tion of platinum - DNA adducts or through inhibition of DNA repair .", "label": "", "metadata": {}, "score": "79.20393"}
{"text": "Postoperative chemoradiation therapy .The role of postoperative therapy ( chemotherapy with or without chemoradiation therapy ) in the management of this disease remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results .", "label": "", "metadata": {}, "score": "79.21247"}
{"text": "Poststudy treatment was at the discretion of the local investigator .The drug was most beneficial for patients with a hepatic load ( ie , percent of the liver that is replaced by cancer ) less than or equal to 10%(ie , limitedtumorspread to the liver ) at study entry .", "label": "", "metadata": {}, "score": "79.30153"}
{"text": "A significant proportion ( approximately one - third ) of patients with pancreatic cancer will present with stage III or locally advanced disease .Patients with stage III pancreatic cancer have tumors that are technically unresectable because of local vessel impingement or invasion by tumor .", "label": "", "metadata": {}, "score": "79.30835"}
{"text": "Bookman et al 1422 \u00a9 2009 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY .Page 5 .and68months , respectively .Ithasbeenpostulatedthatexperimental therapymighthavegreaterimpactinpatientswhohavesmall - volume residual disease , as they have more favorable prognoses .", "label": "", "metadata": {}, "score": "79.38963"}
{"text": "Radiation Therapy Oncology Group .Int J Radiat Oncol Biol Phys 21 ( 5 ) : 1145 - 9 , 1991 .Reni M , Panucci MG , Ferreri AJ , et al .", "label": "", "metadata": {}, "score": "79.53944"}
{"text": "Stage Information for Pancreatic Cancer .The staging system for pancreatic exocrine cancer continues to evolve .The importance of staging beyond establishing whether a tumor is resectable is uncertain since state - of - the - art treatment has demonstrated little impact on survival .", "label": "", "metadata": {}, "score": "79.69794"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. F. Peddi , S. Lubner , R. McWilliams et al . , \" Multi - institutional experience with FOLFIRINOX in pancreatic adenocarcinoma , \" Journal of the Pancreas , vol .", "label": "", "metadata": {}, "score": "79.70038"}
{"text": ": Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer .Ann Surg 228 ( 2 ) : 182 - 7 , 1998 .", "label": "", "metadata": {}, "score": "79.993286"}
{"text": "267 - 277 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. K. Chang , A. L. Johns , and N. D. Merrett , \" Margin clearence and outcome in resected pancreatic cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "80.168655"}
{"text": "Hematology , liver and kidney function are normal , the blood and biochemical indicators should meet the following criteria : .Good understanding and compliance by patients with the pilot program , and provision of informed consent .", "label": "", "metadata": {}, "score": "80.525406"}
{"text": "Int J Radiat Oncol Biol Phys 56 ( 4 Suppl ) : 16 - 23 , 2003 .Kulke MH , Blaszkowsky LS , Ryan DP , et al .", "label": "", "metadata": {}, "score": "80.70584"}
{"text": "[ 5 , 6 ] .Palliative radiation procedures .Pain relief by celiac axis nerve or intrapleural block ( percutaneous ) .[ 7 ] .", "label": "", "metadata": {}, "score": "80.96979"}
{"text": "Check for U.S. clinical trials from NCI 's list of cancer clinical trials that are now accepting patients with recurrent pancreatic cancer .The list of clinical trials can be further narrowed by location , drug , intervention , and other criteria .", "label": "", "metadata": {}, "score": "80.97185"}
{"text": ": Effect of hospital volume on in - hospital mortality with pancreaticoduodenectomy .Surgery 125 ( 3 ) : 250 - 6 , 1999 .Cameron JL , Pitt HA , Yeo CJ , et al .", "label": "", "metadata": {}, "score": "81.012115"}
{"text": "The Gastrointestinal Tumor Study Group .Ann Surg 189 ( 2 ) : 205 - 8 , 1979 .Cohen SJ , Dobelbower R Jr , Lipsitz S , et al .", "label": "", "metadata": {}, "score": "81.21248"}
{"text": "Unusual Cancers of Childhood Treatment ( pancreatic cancer during childhood ) .Incidence and Mortality .Estimated new cases and deaths from pancreatic cancer in the United States in 2015 : [ 1 ] .", "label": "", "metadata": {}, "score": "81.43071"}
{"text": "Duct cell carcinoma ( 90 % of all cases ) .Acinar cell carcinoma .Adenosquamous carcinoma .Cystadenocarcinoma ( serous and mucinous types ) .", "label": "", "metadata": {}, "score": "81.69589"}
{"text": "Although the content of PDQ documents can be used freely as text , it can not be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated .", "label": "", "metadata": {}, "score": "81.747"}
{"text": "Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology , June 2 - 6 , 2006 , Atlanta , GA .", "label": "", "metadata": {}, "score": "81.79434"}
{"text": "Platinum analog or fluoropyrimidine versus single - agent gemcitabine : Many phase III studies have evaluated a combination regimen with either a platinum analog ( cisplatin or oxaliplatin ) or fluoropyrimidine versus single - agent gemcitabine .", "label": "", "metadata": {}, "score": "81.941315"}
{"text": "[ 1 ] These patients may undergo radical cystectomy with pelvic lymph node dissection .The extent of lymph node dissection during cystectomy is controversial [ 2 ] as there are no data from prospective trials demonstrating improved outcomes with lymph node dissection .", "label": "", "metadata": {}, "score": "82.068085"}
{"text": "( C )The potential benefit of experimental treatment regimens evaluated in subpopulations according to the extent of residual disease , illustrated by hazard ratios for survival .", "label": "", "metadata": {}, "score": "82.11862"}
{"text": "In : Edge SB , Byrd DR , Compton CC , et al . , eds . :AJCC Cancer Staging Manual .7th ed .", "label": "", "metadata": {}, "score": "82.20551"}
{"text": "The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system in developing its level - of - evidence designations .Permission to Use This Summary .", "label": "", "metadata": {}, "score": "82.213806"}
{"text": "FOLFIRINOX was more toxic than gemcitabine ; 5.4 % of patients in this group had febrile neutropenia .On the basis of this trial , FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer .", "label": "", "metadata": {}, "score": "82.25121"}
{"text": "FOLFIRINOX was more toxic than gemcitabine ; 5.4 % of patients in this group had febrile neutropenia .On the basis of this trial , FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer .", "label": "", "metadata": {}, "score": "82.25121"}
{"text": "J Clin Oncol 27 ( 23 ) : 3778 - 85 , 2009 .Colucci G , Labianca R , Di Costanzo F , et al .", "label": "", "metadata": {}, "score": "82.37593"}
{"text": "J Clin Oncol 27 ( 23 ) : 3778 - 85 , 2009 .Colucci G , Labianca R , Di Costanzo F , et al .", "label": "", "metadata": {}, "score": "82.37593"}
{"text": "Even overall survival ( OS ) was better in combination arm ( 15.6 months ) compared with a median OS of 9.9 months in monotherapy arm [ 9 ] .", "label": "", "metadata": {}, "score": "82.49128"}
{"text": "Pancreaticoduodenectomy was performed in 64 patients ( 75 % ) and 57 patients ( 66 % ) had R0 resection .Median OS for the whole patients population was 22.7 months while patients who underwent surgery had a median OS of 34 months .", "label": "", "metadata": {}, "score": "82.51095"}
{"text": "Study design .This clinical trial is a prospective open - label RCT .The design of the study integrates rigorous , contemporary clinical research methods in accordance with principles set out in the Declaration of Helsinki and the Guidelines for Good Clinical Practice .", "label": "", "metadata": {}, "score": "82.71303"}
{"text": "Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary .", "label": "", "metadata": {}, "score": "82.718735"}
{"text": "Primary and secondary outcome measures .Primary .Objective response rate ( ORR ) : total of CR + PR .Change in regional lymphatic metastasis ( including number and size ) .", "label": "", "metadata": {}, "score": "82.899765"}
{"text": "Int J Gynecol Cancer 17:547 - 556 , 2007 27 .Vermorken JB , Avall - Lundqvist E , Pfisterer J , Bacon M : The Gynecologic Cancer Intergroup ( GCIG ) : history and current status .", "label": "", "metadata": {}, "score": "82.96994"}
{"text": "Stanley KE ( 1980 )Prognostic factors for survival in patients with inoperable lung cancer .J Natl Cancer Inst 65(1):25 - 32 PubMed .Sweeney CJ , Zhu J , Sandler AB et al ( 2001 )", "label": "", "metadata": {}, "score": "83.08432"}
{"text": "Conclusions .Increasing evidences support the use of neoadjuvant strategies in pancreatic cancer .Nevertheless , the role of neoadjuvant therapy in patients with resectable pancreatic cancer has not yet been defined .", "label": "", "metadata": {}, "score": "83.24629"}
{"text": "Palliation of symptoms may be achieved with conventional treatment .Palliative measures that may improve quality of life while not affecting OS include the following : [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "83.303085"}
{"text": "On the contrary , data about adjuvant chemoradiotherapy in PDAC are more controversial .A few clinical trials have evaluated chemoradiation after surgery with conflicting results ranging from a significant improvement in OS [ 7 ] to a detrimental effect [ 6 ] .", "label": "", "metadata": {}, "score": "83.37209"}
{"text": "Participating Groups PrimarycoordinationwasprovidedbyGOGincollaborationwithGCIG and included the Australia and New Zealand Gynecologic Oncology Group ( Camperdown , Australia ) , MRC - UK ( London , United Kingdom ) , and Isti- tutoMarioNegri(Milan , Italy ) .", "label": "", "metadata": {}, "score": "83.39338"}
{"text": "Arch Surg 136 ( 4 ) : 391 - 8 , 2001 .Sohn TA , Yeo CJ , Cameron JL , et al . :", "label": "", "metadata": {}, "score": "83.502594"}
{"text": "Therefore surgery alone can not be considered the optimal therapy for localized PDAC and complementary treatment ; for example , chemotherapy and radiotherapy have been evaluated in the context of a multimodal approach .", "label": "", "metadata": {}, "score": "83.62362"}
{"text": "du Bois A , Quinn M , Thigpen T , et al : Final document of the 3rd International Gynecologic Can- cer Intergroup Ovarian Cancer Consensus Confer- ence ( GCIG OCCC 2004 ) .", "label": "", "metadata": {}, "score": "83.71583"}
{"text": "The alternate and historical names to identify poorly differentiated NETs include : high grade neuroendocrine carcinoma , large cell neuroendocrine carcinoma , oat cell carcinoma , poorly differentiated endocrine carcinoma , or small cell carcinoma .", "label": "", "metadata": {}, "score": "83.951614"}
{"text": "Warshaw AL , Compton CC , Lewandrowski K , et al .: Cystic tumors of the pancreas .New clinical , radiologic , and pathologic observations in 67 patients .", "label": "", "metadata": {}, "score": "84.02974"}
{"text": "N Engl J Med 369 ( 18 ) : 1691 - 703 , 2013 .Conroy T , Desseigne F , Ychou M , et al .", "label": "", "metadata": {}, "score": "84.11128"}
{"text": "N Engl J Med 369 ( 18 ) : 1691 - 703 , 2013 .Conroy T , Desseigne F , Ychou M , et al .", "label": "", "metadata": {}, "score": "84.11128"}
{"text": "Information about using the illustrations in this summary , along with many other cancer - related images , is available in Visuals Online , a collection of over 2,000 scientific images .", "label": "", "metadata": {}, "score": "84.262856"}
{"text": "NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator .These materials can also be ordered by telephone from the Cancer Information Service toll - free at 1 - 800 - 4-CANCER ( 1 - 800 - 422 - 6237 ) .", "label": "", "metadata": {}, "score": "84.36041"}
{"text": "[ 4 ] .Chemoradiation therapy .The role of chemoradiation in locally advanced pancreatic cancer remains controversial .Table 8 summarizes phase III randomized studies of chemoradiation for stage III pancreatic cancer .", "label": "", "metadata": {}, "score": "84.40203"}
{"text": "Prognosis is so poor in patients with stage IV disease that consideration of entry into a clinical trial is appropriate .The focus of care for many stage IV patients is on palliation of symptoms from bladder tumor that is often massive .", "label": "", "metadata": {}, "score": "84.4527"}
{"text": "[ 2 ] .Risk Factors .Risk factors for development of pancreatic cancer include the following : [ 3 , 4 ] .A family history of pancreatic cancer .", "label": "", "metadata": {}, "score": "84.46036"}
{"text": "Combining radiation therapy with chemotherapy and surgery may kill more tumor cells .PURPOSE : Phase I / II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery .", "label": "", "metadata": {}, "score": "84.663605"}
{"text": "Surgical resection is the mainstay of curative treatment and provides a survival benefit in patients with small , localized pancreatic tumors .Patients with unresectable , metastatic , or recurrent disease are unlikely to benefit from surgical resection .", "label": "", "metadata": {}, "score": "84.682205"}
{"text": "Pancreatic adenocarcinoma ( PDAC ) is the fourth leading cause of cancer deaths among men and women , being responsible for 6 % of all cancer - related deaths .", "label": "", "metadata": {}, "score": "84.69989"}
{"text": "The primary end point was OS and was determined by pairwise comparison to the reference arm , with a 90 % chance of detecting a true hazard ratio of 1.33 that limited type I error to 5 % ( two - tail ) for the four comparisons .", "label": "", "metadata": {}, "score": "84.73167"}
{"text": "The primary end point was OS and was determined by pairwise comparison to the reference arm , with a 90 % chance of detecting a true hazard ratio of 1.33 that limited type I error to 5 % ( two - tail ) for the four comparisons .", "label": "", "metadata": {}, "score": "84.73167"}
{"text": "Acta Oncol .Nilsson O , Van Cutsem E and Delle Fave G : Poorly differentiated carcinomas of the foregut ( gastric , duodenal and pancreatic ) .", "label": "", "metadata": {}, "score": "84.961205"}
{"text": "The development of new interventions beyond surgery and conventional platinum - based chemotherapy is required to additionally improve outcomes for women with advanced EOC .Full - text .", "label": "", "metadata": {}, "score": "84.97493"}
{"text": "The poorly differentiated NETs of the pancreas are characterized by aggressive tumor biology , similar to that of small - cell carcinoma of lung and carry a poor prognosis .", "label": "", "metadata": {}, "score": "85.110725"}
{"text": "Even in recent series a 15 - 35 % rate of R1 resections has been reported , while macroscopically involved margins ( R2 ) have been described in less than 1 % of resections [ 4 ] .", "label": "", "metadata": {}, "score": "85.210175"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Tumor necrosis factor - related apoptosis - inducing ligand ( TRAIL ) based strategy is a promising targeted therapeutic approach for the treatment of a variety of cancers including ovarian cancer .", "label": "", "metadata": {}, "score": "85.48722"}
{"text": "J Clin Oncol 27 ( 11 ) : 1806 - 13 , 2009 .van den Bosch RP , van der Schelling GP , Klinkenbijl JH , et al .", "label": "", "metadata": {}, "score": "85.60571"}
{"text": "Neuroendocrine carcinoma , grade 3 , small cell Neuroendocrine carcinoma , grade 3 , large cell .HPF : high - power fields .Across all types of neuroendocrine neoplasms , prognosis is dependent on both histology and disease extent [ 3].", "label": "", "metadata": {}, "score": "85.727516"}
{"text": "Chemoradiotherapy is a common experimental approach therapy in BRPC .Massucco et al .[ 25 ] evaluated 28 patients with BRPC and nonresectable pancreatic cancer who received gemcitabine - based chemoradiotherapy .", "label": "", "metadata": {}, "score": "85.79393"}
{"text": "Maintenance treatment with capecitabine and bevacizumab extends overall survival in patients with inoperable metastatic colorectal cancer .Chemotherapy in combination with bevacizumab is a standard first - line therapy for patients with metastatic colorectal cancer .", "label": "", "metadata": {}, "score": "85.89016"}
{"text": "\u00a9 2009 by American Society of Clinical Oncology INTRODUCTION After cytoreductive surgery , advanced - stage epi- thelial ovarian carcinoma ( EOC ) initially appears chemotherapy sensitive , as response rates to platinum - based therapy exceed 80 % .", "label": "", "metadata": {}, "score": "85.960205"}
{"text": "They perform specific functions , such as controlling the speed at which food is moved through the GI tract .An estimated 8,000 people in the United States are diagnosed with a neuroendocrine tumor that starts in the GI tract each year .", "label": "", "metadata": {}, "score": "86.043396"}
{"text": ": Pancreaticoduodenectomy for cancer of the head of the pancreas .201 patients .Ann Surg 221 ( 6 ) : 721 - 31 ; discussion 731 - 3 , 1995 .", "label": "", "metadata": {}, "score": "86.18802"}
{"text": ": Pancreaticoduodenectomy for cancer of the head of the pancreas .201 patients .Ann Surg 221 ( 6 ) : 721 - 31 ; discussion 731 - 3 , 1995 .", "label": "", "metadata": {}, "score": "86.18802"}
{"text": "Abstract .Background .Lung cancer is still the leading cause of cancer - related mortality worldwide .Around 80 to 85 % of lung cancers are non - small cell lung cancer ( NSCLC ) .", "label": "", "metadata": {}, "score": "86.33987"}
{"text": "Intention - to - treat ( ITT ) analysis will be applied to minimize bias due to drop - outs .Randomization method .Participants who satisfy the inclusion / exclusion criteria will be randomized in a 1:1 ratio using a computer - generated randomization number table at an independent department ( Center of Evidence - Based Medicine and Clinical Epidemiology ) who will not take part in the following enrollment .", "label": "", "metadata": {}, "score": "86.39363"}
{"text": "About this Chapter .Title .Management of Advanced Non - small Cell Lung Cancer : Front Line Treatment Neoadjuvant Therapy in Pancreatic Cancer : An Emerging Strategy .", "label": "", "metadata": {}, "score": "86.49643"}
{"text": "In addition , internationalmemberswererecruitedforastudy - specificdatasafety and monitoring committee that was charged with ongoing review of safety reportsandwasempoweredtorecommendstudyclosure , asappropriate , on the basis of the results of the IA and other scheduled or unscheduled reports .", "label": "", "metadata": {}, "score": "87.1566"}
{"text": "Borderline Resectable Pancreatic Cancer : Definitions .Borderline resectable cancers have been recently defined as cancers with limited involvement of the mesenteric vessels , such that resection is technically possible , but which carry a high risk of margin - positive resection and consequently a higher risk of recurrence [ 22 ] .", "label": "", "metadata": {}, "score": "87.316795"}
{"text": "Late pelvic toxicity following bladder - sparing therapy in patients with invasive bladder cancer : analysis of RTOG 89 - 03 , 95 - 06 , 97 - 06 , 99 - 06 .", "label": "", "metadata": {}, "score": "87.34363"}
{"text": "PubMed .Alberola V , Camps C , Provencio M , Isla D , Rosell R , Vadell C , Bover I , Ruiz - Casado A , Azagra P , Jimenez U , et al .", "label": "", "metadata": {}, "score": "87.38648"}
{"text": "As anticipated , the extent of cytoreductive surgery remains an important prognostic factor for OS ( Fig 4A ) , second only to stage at diagnosis .", "label": "", "metadata": {}, "score": "88.03544"}
{"text": "Non - Small Cell Lung Cancer .Br J Cancer 83(4):447 - 453 PubMed CrossRef .( 1999 ) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "88.04028"}
{"text": "MRC Advanced Bladder Cancer Working Party .Br J Cancer 78 ( 8) : 1067 - 75 , 1998 .Petrioli R , Frediani B , Manganelli A , et al .", "label": "", "metadata": {}, "score": "88.11592"}
{"text": "The mean , median , standard deviation , maximum , and minimum will be calculated for quantitative variables , and the absolute and relative frequency , ratio , and CI calculated for qualitative and ranked variables .", "label": "", "metadata": {}, "score": "88.12653"}
{"text": "The efficacy of gemcitabine for poorly differentiated NET of the pancreas remains unclear and we believe that our case series provide more evidence that gemcitabine can offer palliative benefit to patients who have ECOG performance status 0 - 2 and are willing to receive more therapy .", "label": "", "metadata": {}, "score": "88.206436"}
{"text": "Thedateoflastcontact wasusedtocalculateacensoredtimeatriskforpatientswithoutdocumented progression(PFS)orforthosewhohadnoreporteddeath(OS ) .Adverse events considered at least possibly related to treatment were categorized , graded , and reported according to National Cancer Institute Common Toxicity Criteria version 2.0 .", "label": "", "metadata": {}, "score": "88.38201"}
{"text": "Jason E. Faris , MD ( Massachusetts General Hospital ) .Jennifer Wo , MD ( Massachusetts General Hospital ) .Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site 's Contact Form .", "label": "", "metadata": {}, "score": "88.54573"}
{"text": "In this scenario , preoperative treatment may be specifically beneficial in borderline resectable PDAC , improving the fraction of patients undergoing radical resection .Table 1 : Comparison of definitions of borderline resectable pancreatic cancer .", "label": "", "metadata": {}, "score": "88.63748"}
{"text": "J Clin Oncol 28 ( 10 ) : 1645 - 51 , 2010 .Von Hoff DD , Ervin T , Arena FP , et al .", "label": "", "metadata": {}, "score": "88.79303"}
{"text": "J Clin Oncol 28 ( 10 ) : 1645 - 51 , 2010 .Von Hoff DD , Ervin T , Arena FP , et al .", "label": "", "metadata": {}, "score": "88.79303"}
{"text": "Pancreatic Cancer Treatment ( PDQ \u00ae ) : Treatment - Health Professional Information [ NCI ] .This information is produced and provided by the National Cancer Institute ( NCI ) .", "label": "", "metadata": {}, "score": "88.829704"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer .", "label": "", "metadata": {}, "score": "89.010216"}
{"text": "+1 - 617.636.5627 Fax :+1 - 617.636.8535 E - mail : wsaif@tuftsmedicalcenter.org .References .Dimou AT , Syrigos KN and Saif MW : Neuroendocrine tumors of the pancreas : what 's new .", "label": "", "metadata": {}, "score": "89.012505"}
{"text": "Invasive local treatment failure [ Time Frame : From start of protocol treatment to date of local failure .Analysis occurs after all patients have copmleted treatment . ]", "label": "", "metadata": {}, "score": "89.03847"}
{"text": "Cancer 78 ( 3 Suppl ) : 615 - 26 , 1996 .Cellular Classification of Pancreatic Cancer .Pancreatic cancer includes the following carcinomas : .", "label": "", "metadata": {}, "score": "89.44078"}
{"text": "Stage I and Stage II Pancreatic Cancer Treatment .Treatment Options for Stages I and II Pancreatic Cancer .Treatment options for stages I and II pancreatic cancer include the following : .", "label": "", "metadata": {}, "score": "89.62944"}
{"text": "Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "89.748856"}
{"text": "Bajorin DF : Paclitaxel in the treatment of advanced urothelial cancer .Oncology ( Huntingt ) 14 ( 1 ) : 43 - 52 , 57 ; discussion 58 , 61 - 2 , 2000 .", "label": "", "metadata": {}, "score": "89.78089"}
{"text": "Purpose of This Summary .This PDQ cancer information summary for health professionals provides comprehensive , peer - reviewed , evidence - based information about the treatment of pancreatic cancer .", "label": "", "metadata": {}, "score": "89.909195"}
{"text": "Deaths : 40,560 .The incidence of carcinoma of the pancreas has markedly increased over the past several decades and ranks as the fourth leading cause of cancer death in the United States .", "label": "", "metadata": {}, "score": "89.91174"}
{"text": "Br J Surg 85 ( 2 ) : 199 - 201 , 1998 .van den Bosch RP , van der Schelling GP , Klinkenbijl JH , et al .", "label": "", "metadata": {}, "score": "89.9211"}
{"text": "Board members will not respond to individual inquiries .Levels of Evidence .Some of the reference citations in this summary are accompanied by a level - of - evidence designation .", "label": "", "metadata": {}, "score": "90.19345"}
{"text": "J Clin Oncol 25 ( 30 ) : 4787 - 92 , 2007 .Polati E , Finco G , Gottin L , et al .", "label": "", "metadata": {}, "score": "90.21999"}
{"text": "For a detailed description of the disclosure categories , or for more information about ASCO 's conflict of interest policy , please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors .", "label": "", "metadata": {}, "score": "90.2229"}
{"text": "Sanchez JA , Newman KD , Eichelberger MR , et al .:The papillary - cystic neoplasm of the pancreas .An increasingly recognized clinicopathologic entity .", "label": "", "metadata": {}, "score": "90.42504"}
{"text": "Relativetothereferencearm , theadjustedriskoffirstprogressionordeath(PFS)rangedfrom0.984 to1.066fortheexperimentalregimens(Fig3A ) .Theadjustedrelative risks of death ranged from 0.952 to 1.114 ( Fig 3B ) .Anexploratoryanalysisofhazardratios(HRs)forsurvivalonthe basis of diagnosis ( EOC v PPC ) , age ( ? 65 v ?", "label": "", "metadata": {}, "score": "90.562675"}
{"text": "We identified that caspase-8 and not the modulation of TRAIL receptors is required for the combination effect of TRAIL and mdivi-1 .We further demonstrated that the enhanced efficacy of combination of mdivi-1 and death ligands is not dependent on the originally reported target of mdivi-1 , Drp1 , and is also not dependent on the two important pro - apoptotic Bcl-2 family proteins Bax and Bak .", "label": "", "metadata": {}, "score": "90.585655"}
{"text": "Palliative therapy .Palliative therapy for advanced pancreatic cancer includes the following : .Pain - relieving procedures ( e.g. , celiac or intrapleural block ) and supportive care .", "label": "", "metadata": {}, "score": "90.63928"}
{"text": "Ann Surg 230 ( 6 ) : 776 - 82 ; discussion 782 - 4 , 1999 .Neoptolemos JP , Dunn JA , Stocken DD , et al .", "label": "", "metadata": {}, "score": "90.66716"}
{"text": "Br J Surg 85 ( 2 ) : 199 - 201 , 1998 .Royal RE , Wolfe RA , Crane CH : Cancer of the pancreas .", "label": "", "metadata": {}, "score": "90.730316"}
{"text": "Peto R , Peto J : Asymptotically efficient rank invariant procedures .J Roy Stat Soc A 135:185 - 206 , 1972 ; discussion 199 - 206 13 .", "label": "", "metadata": {}, "score": "90.80362"}
{"text": "[Abstract ] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium , Feb 14 - 16 , 2008 , San Francisco , CA .A-288 , 2008 .", "label": "", "metadata": {}, "score": "91.1198"}
{"text": "Invasive adenocarcinoma associated with cystic mucinous neoplasm or intraductal papillary mucinous neoplasm .Pancreatoblastoma .Papillary - cystic neoplasm ( Frantz tumor ) .This tumor has lower malignant potential and may be cured with surgery alone .", "label": "", "metadata": {}, "score": "91.47709"}
{"text": "J Clin Oncol 15 ( 6 ) : 2403 - 13 , 1997 .Storniolo AM , Enas NH , Brown CA , et al .", "label": "", "metadata": {}, "score": "91.593155"}
{"text": "This information is produced and provided by the National Cancer Institute ( NCI ) .The information in this topic may have changed since it was written .", "label": "", "metadata": {}, "score": "91.62514"}
{"text": "Examinations .Baseline examinations before treatment .Medical history and demographic information , including sex , age , address , and telephone details .Physical examination : height , weight , body surface area , and vital signs , including heart rate , blood pressure , respiration rate , and temperature .", "label": "", "metadata": {}, "score": "91.70883"}
{"text": "N Engl J Med 344 ( 22 ) : 1681 - 7 , 2001 .Polati E , Finco G , Gottin L , et al .", "label": "", "metadata": {}, "score": "91.915375"}
{"text": "However , the efficacy of these treatments in neoadjuvant setting needs to be verified in prospective clinical trials .Conflict of Interests .The authors declare that there is no conflict of interests regarding the publication of this paper .", "label": "", "metadata": {}, "score": "91.99364"}
{"text": "Neoadjuvant Therapy in Resectable Pancreatic Cancer .Neoadjuvant treatment has a strong rationale in pancreatic cancer and presents many theoretical advantages .Indeed , preoperative chemotherapy approach allows an early treatment of micrometastatic disease , responsible for relapse after curative surgery .", "label": "", "metadata": {}, "score": "92.2341"}
{"text": "Laboratory examinations : routine blood and urine tests , liver and renal function .Electrocardiography ( ECG ) and chest computed tomography ( CT ) scans .", "label": "", "metadata": {}, "score": "92.25545"}
{"text": "Allergy to drugs .Pregnancy or lactation .History of cardiovascular disease ( CVD ) , including congestive heart failure ( higher than New York Heart Association level II ) .", "label": "", "metadata": {}, "score": "92.26921"}
{"text": "Hospitals in your area may have information about local and regional agencies that have information on finances , getting to and from treatment , receiving care at home , and dealing with problems related to cancer treatment .", "label": "", "metadata": {}, "score": "92.6028"}
{"text": "Ann Surg 219 ( 1 ) : 18 - 24 , 1994 .Baron TH : Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract .", "label": "", "metadata": {}, "score": "93.05238"}
{"text": "Bethesda , MD 20892 - 9760 .Search the NCI Web site .The NCI Web site provides online access to information on cancer , clinical trials , and other Web sites and organizations that offer support and resources for cancer patients and their families .", "label": "", "metadata": {}, "score": "93.25414"}
{"text": "Get More Information From NCI .Call 1 - 800 - 4-CANCER .For more information , U.S. residents may call the National Cancer Institute 's ( NCI 's ) Cancer Information Service toll - free at 1 - 800 - 4-CANCER ( 1 - 800 - 422 - 6237 ) Monday through Friday from 8:00 a.m. to 8:00 p.m. , Eastern Time .", "label": "", "metadata": {}, "score": "93.72646"}
{"text": "Authors ' Affiliations .Department of Respiratory Diseases , The First Affiliated Hospital of Third Military Medical University .Center of Evidence - Based Medicine and Clinical Epidemiology , The Second Affiliated Hospital of Third Military Medical University .", "label": "", "metadata": {}, "score": "93.86987"}
{"text": "Antineoplastic Agents Antiviral Agents Enzyme Inhibitors Immunologic Factors Immunosuppressive Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Radiation - Sensitizing Agents Therapeutic Uses", "label": "", "metadata": {}, "score": "93.89021"}
{"text": "Palliative surgery : palliative surgical biliary and/or gastric bypass , percutaneous radiologic biliary stent placement , or endoscopic biliary stent placement .[ 2 , 3 ] .", "label": "", "metadata": {}, "score": "94.31288"}
{"text": "ULN : .Upper limit of normal .WBCC : . white blood cell count .WHO : . World Health Organization .Declarations .Acknowledgments .", "label": "", "metadata": {}, "score": "94.33026"}
{"text": "Description of the AE and associated symptoms .When did the AE happen ?What was the severity of the AE ?How long did the AE last ?", "label": "", "metadata": {}, "score": "95.4301"}
{"text": "PubMed .Stathopoulos GP , Antoniou D , Dimitroulis J , Michalopoulou P , Bastas A , Marosis K , Stathopoulos J , Provata A , Yiamboudakis P , Veldekis D , et al .", "label": "", "metadata": {}, "score": "95.43964"}
{"text": "Board members review recently published articles each month to determine whether an article should : . be discussed at a meeting , . be cited with text , or .", "label": "", "metadata": {}, "score": "95.453415"}
{"text": "Gastrointestinal Tumor Study Group .Cancer 59 ( 12 ) : 2006 - 10 , 1987 .Kalser MH , Ellenberg SS : Pancreatic cancer .", "label": "", "metadata": {}, "score": "95.51075"}
{"text": "Pain : Celiac axis and intrapleural nerve blocks can provide highly effective and long - lasting control of pain for some patients .( Refer to the PDQ summary on Pain for more information . )", "label": "", "metadata": {}, "score": "95.78574"}
{"text": "The results for a wide range of search terms will include a list of \" Best Bets , \" editorially chosen Web pages that are most closely related to the search term entered .", "label": "", "metadata": {}, "score": "95.86142"}
{"text": "Pancreatic ductal adenocarcinoma ( PDAC ) is an aggressive disease and still continues to have the worst prognosis of all gastrointestinal malignancies .Despite considerable advances in radiological techniques , it often presents as a locally advanced or metastatic disease in most patients and only about 10 - 20 % of patients are considered candidate to surgery [ 1 ] .", "label": "", "metadata": {}, "score": "95.88159"}
{"text": "Helical computed tomographic scan .Magnetic resonance imaging scan .Endoscopic ultrasound .Minimally invasive techniques , such as laparoscopy and laparoscopic ultrasound may be used to decrease the use of laparotomy .", "label": "", "metadata": {}, "score": "95.88275"}
{"text": "Ann Oncol 7 ( 4 ) : 347 - 53 , 1996 .Burris HA 3rd , Moore MJ , Andersen J , et al .", "label": "", "metadata": {}, "score": "95.92987"}
{"text": "More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI 's Comprehensive Cancer Database pages .", "label": "", "metadata": {}, "score": "95.93155"}
{"text": "Surgery 111 ( 5 ) : 489 - 94 , 1992 .Brennan MF , Moccia RD , Klimstra D : Management of adenocarcinoma of the body and tail of the pancreas .", "label": "", "metadata": {}, "score": "96.257614"}
{"text": "Chat online .The NCI 's LiveHelp \u00ae online chat service provides Internet users with the ability to chat online with an Information Specialist .The service is available from 8:00 a.m. to 11:00 p.m. Eastern time , Monday through Friday .", "label": "", "metadata": {}, "score": "96.70886"}
{"text": "J Clin Oncol 2000 , 18 : 122 - 130 .PubMed .Copyright .\u00a9 Hu et al . ; licensee BioMed Central Ltd. 2013 .", "label": "", "metadata": {}, "score": "96.87361"}
{"text": "GI cancers include those of the esophagus , stomach , liver , pancreas , biliary tract , small bowel , appendix , colon , rectum , and anus .", "label": "", "metadata": {}, "score": "97.37091"}
{"text": "General Information About Pancreatic Cancer .This summary provides information about the treatment of exocrine pancreatic cancer .Other PDQ summaries containing information related to cancer in the pancreas include the following : .", "label": "", "metadata": {}, "score": "97.44003"}
{"text": "Stage III Pancreatic Cancer Treatment .Treatment Options for Stage III Pancreatic Cancer .While stage III and stage IV pancreatic cancer are both incurable , the natural history of stage III ( locally advanced ) disease may be different than it is for stage IV disease .", "label": "", "metadata": {}, "score": "98.05355"}
{"text": "Presence of severe organic disease , including active infection or CVD .Poor hepatic function or severe cirrhosis .Abnormal blood coagulation indicators .Poor condition or cachexia .", "label": "", "metadata": {}, "score": "98.30426"}
{"text": "Fatigue .Diagnostic and Staging Evaluation .Pancreatic cancer is difficult to detect and diagnose for the following reasons : .There are no noticeable signs or symptoms in the early stages of pancreatic cancer .", "label": "", "metadata": {}, "score": "98.388985"}
{"text": "Write to us .For more information from the NCI , please write to this address : .NCI Public Inquiries Office .9609 Medical Center Dr. .", "label": "", "metadata": {}, "score": "98.43721"}
{"text": "Clinical Features .Pancreatic cancer symptoms depend on the site of the tumor within the pancreas and the degree of tumor involvement .In the early stages of pancreatic cancer there are not many noticeable symptoms .", "label": "", "metadata": {}, "score": "98.86673"}
{"text": "Corresponding author : Michael A. Bookman , MD , Fox Chase Cancer Center , 333 Cottman Ave , W41 , Phila- delphia , PA 19111 michael . bookman@fccc.edu .", "label": "", "metadata": {}, "score": "98.92337"}
{"text": "Relief of gastric outlet obstruction .Pain control .Psychological care to address the potentially disabling psychological events associated with the diagnosis and treatment of pancreatic cancer .", "label": "", "metadata": {}, "score": "98.971466"}
{"text": "J Clin Oncol 25 ( 3 ) : 326 - 31 , 2007 .Rothenberg ML , Moore MJ , Cripps MC , et al .", "label": "", "metadata": {}, "score": "99.01208"}
{"text": "Muhammad Wasif Saif 1 , Kristin Kaley 2 , Teresa Rodriguez 3 , Marie Carmel Garcon 3 . 1 Section of GI Cancers and Experimental Therapeutics , Tufts University School of Medicine .", "label": "", "metadata": {}, "score": "101.60028"}
{"text": "AUTHORS ' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST Although all authors completed the disclosure declaration , the following author(s ) indicated a financial or other interest that is relevant to the subject matter under consideration in this article .", "label": "", "metadata": {}, "score": "101.632355"}
{"text": "Complications of pancreatic cancer include the following : .Malabsorption : Frequently , malabsorption caused by exocrine insufficiency contributes to malnutrition .Attention to pancreatic enzyme replacement can help alleviate this problem .", "label": "", "metadata": {}, "score": "101.763"}
{"text": "Contact Us .More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page .", "label": "", "metadata": {}, "score": "103.15997"}
{"text": "\" The preferred citation for this PDQ summary is : .National Cancer Institute : PDQ \u00ae Pancreatic Cancer Treatment .Bethesda , MD : National Cancer Institute .", "label": "", "metadata": {}, "score": "103.318954"}
{"text": "Treatment Options for Recurrent Pancreatic Cancer .Treatment options for recurrent pancreatic cancer include the following : .Palliative therapy for recurrent pancreatic cancer includes the following : .", "label": "", "metadata": {}, "score": "103.51947"}
{"text": "Obesity .Chronic pancreatitis .Anatomy .Anatomy of the pancreas .Cancers of the pancreas are commonly identified by the site of involvement within the pancreas .", "label": "", "metadata": {}, "score": "103.73453"}
{"text": "Healthwise , Incorporated disclaims any warranty or liability for your use of this information .Your use of this information means that you agree to the Terms of Use .", "label": "", "metadata": {}, "score": "104.40585"}
{"text": "Baron TH : Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract .N Engl J Med 344 ( 22 ) : 1681 - 7 , 2001 .", "label": "", "metadata": {}, "score": "104.961075"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "105.61084"}
{"text": "Healthwise disclaims any liability for the decisions you make based on this information .Some material in CancerNet \u2122 is from copyrighted publications of the respective copyright claimants .", "label": "", "metadata": {}, "score": "106.57215"}
{"text": "Healthwise , Healthwise for every health decision , and the Healthwise logo are trademarks of Healthwise , Incorporated .Clinical Studies .Gynecologic Oncology Group ( GOG ) Studies .", "label": "", "metadata": {}, "score": "106.698555"}
{"text": "Whipple procedure ( pancreaticoduodenal resection ) .Total pancreatectomy when necessary for adequate margins .Distal pancreatectomy for tumors of the body and tail of the pancreas .", "label": "", "metadata": {}, "score": "107.01897"}
{"text": "The pancreas is obscured by other organs in the abdomen and is difficult to visualize clearly on imaging tests .To appropriately treat pancreatic cancer , it is crucial to evaluate whether the cancer can be resected .", "label": "", "metadata": {}, "score": "108.333046"}
{"text": "Declaration of interest The authors state no conflict of interest and have received no payment in preparation of this manuscript or conduct of the study .", "label": "", "metadata": {}, "score": "111.09567"}
{"text": "Received 7 April 2014 ; Accepted 11 June 2014 ; Published 1 July 2014 .Copyright \u00a9 2014 Alessandro Bittoni et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "112.23172"}
{"text": "Jaundice .Light - colored stools or dark urine .Pain in the upper or middle abdomen and back .Weight loss for no known reason .", "label": "", "metadata": {}, "score": "115.50156"}
{"text": "9th ed .Philadelphia , Pa : Lippincott Williams & Wilkins , 2011 , pp 961 - 89 .Changes to This Summary ( 07 / 10 / 2015 ) .", "label": "", "metadata": {}, "score": "115.72804"}
{"text": "Accessed .Images in this summary are used with permission of the author(s ) , artist , and/or publisher for use within the PDQ summaries only .", "label": "", "metadata": {}, "score": "115.7373"}
{"text": "2 Yale School of Medicine .New Haven , CT , USA .3 Columbia University Medical Center .New York , NY , USA .", "label": "", "metadata": {}, "score": "127.748924"}
